Skip to Content
DiagnosticsDiagnostics
  • Review
  • Open Access

25 March 2026

35 Pages

Therapeutic Termination of Pregnancy Under the Umbrella of Environmental, Socio-Economic Factors and High-Risk Pregnancy

,
,
,
,
,
,
,
and
1
Department PhD, IOSUD-Institution Offering Doctoral Studies, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
2
Department of Obstetrics and Gynecology, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
3
“Bucur” Maternity, Saint John Hospital, 012361 Bucharest, Romania
4
Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania

Simple Summary

Therapeutic abortion is a procedure that is performed in well-established medical situations. The aim of this review is to explore medical, psychological, social, and legal aspects regarding the decision to undergo the interruption of pregnancy. Furthermore, we considered it necessary to describe the current diagnostic tools and to outline the key risk factors (such as maternal age, genetic conditions and psychiatric disorders). The importance of counseling, awareness of ethical dilemmas and safe access to care is emphasized, especially in countries with restrictive abortion laws. Therefore, it is important to understand these factors in order to ensure the necessary care and support for women facing this complex situation.

Abstract

Therapeutic termination of pregnancy (TToP) represents an intervention that is performed for medical reasons, such as risks to maternal health or severe fetal anomalies. Advances in prenatal screening and diagnostic tools—including serum markers, ultrasound, cell-free fetal DNA, chorionic villus sampling and amniocentesis—have significantly improved early detection and clinical decision-making. This narrative review synthesizes current knowledge on the genetic, environmental and psychosocial determinants that influence the decision of the patients to pursue TToP. The literature search was performed primarily using PubMed database, while Scopus and Google Scholar were used to identify additional relevant studies. Some of the selected studies, as well as certain sections of this review, address both therapeutic and voluntary termination of pregnancy, whereas others focus exclusively on TToP. Moreover, this review describes the types of abortion (medical or surgical/aspiration) along with their management strategies to prevent or address potential complications. It is well known that demographic, cultural and socio-economic factors continue to influence the access to TToP, as well as the perceptions of it. Psychiatric comorbidities (such as anxiety, affective and psychotic disorders) are observed with a higher prevalence among women undergoing TToP and may influence both the decision and psychological outcomes post-procedure. While most women report emotional relief after TToP, some of them experience depression, post-traumatic stress disorder or substance misuse. Legal and ethical considerations further complicate access to safe abortion, leading to situations where patients may resort to unsafe procedures, which result in higher rates of morbidity and mortality. Data from the EUROCAT network show rising trends in congenital anomalies like trisomy 13, trisomy 18 and caudal regression syndrome (conditions commonly associated with TToP). Therefore, it is mandatory to form a multidisciplinary team in these cases, integrating medical, psychological and ethical dimensions. Ensuring safe, evidence-based and compassionate access to TToP remains a critical component of reproductive healthcare.

1. Introduction

Therapeutic termination of pregnancy (TToP) is a procedure of induced abortion for medical reasons (either to prevent significant harm to the mother or due to fetal unviability). In many jurisdictions, legal thresholds for TToP differ according to gestational age and the maternal or fetal indication [1,2]. Unlike voluntary termination of pregnancy (VToP), which is based on the individual’s choice, TToP requires a physician’s clinical evaluation, making it both a traumatic obstetric event and a procedure with an inherent therapeutic purpose. The decision of whether to terminate a pregnancy, either voluntarily or therapeutically, is a very personal one and is determined by many factors, while broader socio-cultural and economic conditions impact attitudes toward family planning, contraceptive use and abortion. For example, during the COVID-19 pandemic, therapeutic abortion was considered in specific cases of severe respiratory failure. Preterm delivery, as well as TToP, were suggested as possible options to reduce intra-abdominal pressure in pregnant women requiring mechanical ventilation. Furthermore, continuation of pregnancy could limit the use of antiviral or immunomodulatory therapies, given that their fetal safety profiles were not fully established [3,4,5].
Intrauterine development can be either normal or abnormal, with disruptions caused by genetic disorders, environmental factors or a combination of both. These disturbances affect cytogenesis, histogenesis as well as morphogenesis, resulting in congenital anomalies (CAs) at birth [6]. Accounting for a significant proportion of prenatal and neonatal deaths worldwide, CAs are a major global childhood health issue, with prevalence rates ranging from 39.7 per 1000 live births in high-income regions to 82 per 1000 in low-income areas [7]. In many cases, the affected infants do not survive, with more than 70% of them dying within the first month of life. However, even when survival is possible, the treatment is often expensive and full recovery is not always achievable [8].
Although the exact causes of various CAs remain unknown (40–60%), genetic abnormalities, environmental influences and multifactorial inheritance are recognized as key risk factors. Genetic disorders stem from chromosomal abnormalities (which manifest as numerical or structural changes) or single-gene mutations, both contributing to birth defects [6,8].
Birth defects and genetic disorders affect approximately 3% to 5% of pregnancies and are considered a significant cause of infant and childhood mortality [9]. Chromosomal abnormalities (including structural or numerical alterations such as aneuploidy, translocations, duplications and deletions) occur in 1/150 live births. Trisomy 21 (Down syndrome) stands as the most prevalent chromosomal disorder with a birth incidence of 1 in 800, while trisomy 13 and trisomy 18 occur less frequently (but are often associated with elevated infant mortality rates). Sex chromosome aneuploidies are rarer than autosomal aneuploidies. Monosomy X (known as Turner syndrome) is the only monosomy compatible with life [10].
The risk of aneuploidy increases with maternal age, but other factors, such as ultrasound findings, past obstetric history, and familial genetic conditions, also play a role [10]. It was observed that the likelihood of recurrence increases if there was a previous pregnancy affected by aneuploidy or another genetic disorder, especially if one of the parents is a carrier of a balanced Robertsonian translocation. However, the majority of cases are sporadic due to chromosomal nondisjunction.
The identification and prevention of environmental causes of congenital anomalies is crucial. Approximately 10% of these anomalies are attributed to such factors and may be prevented through appropriate interventions. Teratogens that affect the human embryo during critical phases of development can cause malformations by disrupting normal development (particularly during rapid organ differentiation) [8,11,12]. Potential risk factors include maternal infections, advanced maternal age, drug intake and exposure to substances (such as caffeine, nicotine, commonly used medications and hazardous waste). Some studies have also described that maternal nutritional status, alcohol consumption, obesity, diabetes, parental race, socio-economic status and hyperthermia during early pregnancy are all linked to congenital anomalies (CAs) [6]. Certain chemical substances, including mercury, lead and arsenic, also contribute to congenital abnormalities. It has been shown that mercury exposure can lead to neurological impairments resembling cerebral palsy. Moreover, lead was linked to fetal growth restriction and neurological disorders [6,12]. Furthermore, radiation exposure (e.g., X-rays), depending on dose and timing, may lead to congenital malformations such as spina bifida, cleft palate, limb abnormalities, visual impairment, or microcephaly [8].
Multifactorial inheritance, involving complex gene–gene and gene–environment interactions, plays a significant role in congenital malformations [11,13]. Some studies using mouse models of neural tube defects have demonstrated the impact of these interactions on the development of CAs [11].

2. Materials and Methods

This narrative review was conducted to synthesize the current knowledge on the genetic, environmental and psychosocial determinants that influence the decision of patients to pursue therapeutic termination of pregnancy (TToP). Furthermore, this review aimed to describe the available prenatal screening and diagnostic tools—including serum markers, ultrasound, cell-free fetal DNA (cfDNA), chorionic villus sampling (CVS) and amniocentesis—the types of abortion procedures (medical and surgical/aspiration) along with their management strategies, the role of psychiatric comorbidities in the decision-making process and post-procedure outcomes, as well as the ethical, religious and legal considerations surrounding TToP.
The literature search was performed primarily using the PubMed database, while Scopus and Google Scholar were used to identify additional relevant studies. The search strategy included the following key terms, used individually and in combination: “therapeutic abortion”, “therapeutic termination of pregnancy”, “congenital anomalies”, “prenatal screening”, “prenatal diagnosis”, “chromosomal abnormalities”, “psychiatric comorbidities”, “reproductive rights” and “abortion ethics”. Boolean operators (AND, OR) were employed to refine the search results. No restrictions were applied regarding the publication date. The majority of the included references were published between 2010 and 2025, although a limited number of earlier seminal studies were also considered where relevant. Priority was given to original research articles, systematic reviews and clinical practice guidelines published in peer-reviewed journals. Reference lists of key articles were also screened to identify further pertinent publications.
It should be noted that some of the selected studies, as well as certain sections of this review, address both therapeutic and voluntary termination of pregnancy (VToP), whereas others focus exclusively on TToP. Studies were included if they provided relevant data on the medical, psychological, sociodemographic or legal aspects of pregnancy termination. The types of included studies comprised observational studies (cross-sectional, cohort and case–control designs), randomized controlled trials, systematic reviews and meta-analyses, clinical practice guidelines (e.g., ACOG Practice Bulletins), and epidemiological surveillance reports (e.g., EUROCAT/JRC reports). Editorials, commentaries and non-peer-reviewed sources were excluded. The findings were organized thematically into the following categories: prenatal screening and diagnostic methods, sociodemographic and reproductive factors influencing TToP, psychopathological determinants and outcomes, medical and surgical methods of termination, epidemiological trends from the EUROCAT network, as well as ethical, religious and legal considerations.

3. Screening and Diagnostic Testing

Women may seek prenatal screening or diagnostic testing for multiple reasons, such as the consideration of pregnancy termination in cases where severe fetal anomalies are detected. The early detection of such anomalies enables parents to make informed decisions, which may include opting for medical interventions, planning for specialized care or choosing TToP if the condition is incompatible with life (or significantly affects the quality of life) [14]. It has been observed that neural tube defects can be treated prenatally, which may lead to better neonatal outcomes. The ethical and emotional nature of these decisions requires that patients receive detailed counseling about the risks, benefits and limitations of the tests that are available. Appropriate guidance, aligned with their values and medical needs, should be offered by genetic counselors and healthcare providers.

3.1. Screening Tests

Prenatal testing is primarily conducted as a screening tool to assess the likelihood of chromosomal abnormalities or birth defects. The testing methods used for prenatal screening include serum screening, carrier screening and ultrasound. The ultrasound test delivers precise diagnoses for open neural tube defects, but serum screening generates only probability results. Various serum screening options exist, differing in testing criteria and timing [10].

3.1.1. First-Trimester Screening

The first-trimester screening is conducted between 10 weeks and 13 weeks, 6 days of gestation. This screening test is used to assess the risk of chromosomal abnormalities through serum marker analysis combined with ultrasound evaluation. The serum test measures free beta-human chorionic gonadotropin (hCG) and pregnancy-associated plasma protein A (both markers are collected during the 9 to 13 weeks, 6-day period). This data, along with maternal age, prior pregnancy history, fetal count, weight, race and nuchal translucency measurement (NT), is used to estimate the risk (with some models also considering the presence of the nasal bone). The risk is expressed as a ratio, with 1 in 300 often considered the threshold for high risk, although this varies by laboratory. The detection rate for trisomy 21 ranges from 82% to 87%, with a 5% false-positive rate [10,15,16].
Pregnant individuals who have an enlarged nuchal translucency need to undergo targeted ultrasound and fetal echocardiography regardless of their aneuploidy status [10].
The primary advantage of first-trimester screening is the early availability of results, enabling further diagnostic testing, genetic counseling, and timely consideration of TToP (in severe or lethal cases). The measurement accuracy requires trained sonographers because measurement variations as small as 0.5 mm can significantly affect sensitivity [17]. The detection ability of this test exceeds the quadruple marker screen, but its performance weakens after 13 weeks of gestation (with maximum success at 11 weeks of pregnancy) [18].
Table 1 summarizes major structural anomalies that may be identified during the first trimester scan, along with their diagnostic features and clinical implications.
Table 1. Major fetal structural anomalies detectable during 11–13 + 6 weeks ultrasound scan and their prognostic implications.

3.1.2. Quadruple Marker Screening

The quadruple marker screen (quad screen) was introduced in the 1990s and remains widely used for patients who seek care after the first trimester (serving more than 25% of patients in public health clinics). This test is performed between 15 and 22 weeks of pregnancy and measures human chorionic gonadotropin (hCG), alpha-fetoprotein (AFP), inhibin A and unconjugated estriol. It estimates the risk of chromosomal abnormalities by combining serum marker results with maternal factors such as age, race, weight, fetal count, diabetes status and gestational age. The quad screen detects approximately 81% of trisomy 21 cases with a 5% false-positive rate, making its detection rate slightly lower than that of first-trimester screening [10].
A key advantage of the quad screen is its ability to detect open neural tube defects through AFP levels, as this protein is produced by the fetus and can be detected in both amniotic fluid and maternal serum. The quad test offers better accessibility because it does not need specialized sonography equipment, which makes it available in various healthcare facilities. Variations of this test exist, such as the triple screen (which excludes inhibin A) [52] and the penta screen (which incorporates hyperglycosylated hCG) [53]. However, these alternatives do not significantly improve diagnostic performance.

3.1.3. Cell-Free Fetal DNA Screening

Non-invasive prenatal screening (NIPS) using cell-free DNA (cfDNA) has revolutionized aneuploidy detection since 2011. The analysis of fetal DNA fragments in maternal blood requires a fetal fraction above 4% to generate reliable results. The detection rate for trisomy 21 reaches 99%, though the accuracy for trisomies 18 and 13 is slightly lower [54,55].
Despite its high sensitivity, cfDNA remains a screening tool rather than a diagnostic test. The positive predictive value (PPV) of aneuploidy tests depends on the prevalence of aneuploidy in the population, so confirmatory testing with chorionic villus sampling (CVS) or amniocentesis is required before TToP. Cases of premature pregnancy termination without diagnostic confirmation have been reported due to misinterpretation, highlighting the need for genetic counseling and ultrasound evaluation prior to testing [56,57].
Beyond aneuploidy, cfDNA can determine fetal sex, Rh status, and, in some cases, microdeletions and other aneuploidies. However, these additional tests remain unvalidated and have a low PPV. The following conditions may produce false-positive results in cfDNA tests: maternal chromosomal abnormalities, confined placental mosaicism, malignancies and vanishing twin syndrome [58,59]. While cfDNA is the most sensitive test for trisomy 21, traditional sequential screening remains superior for detecting a broader range of chromosomal abnormalities.

3.1.4. Ultrasound Screening

During prenatal care, ultrasound is commonly used to determine gestational age and detect structural abnormalities in the fetus. Many patients opt for ultrasound-only screening, especially second-trimester transabdominal ultrasonography (18–23 weeks), to assess fetal anatomy. First-trimester ultrasounds (whether transvaginal or transabdominal) help confirm viability, detect multiple gestations and identify major anomalies (like anencephaly or cystic hygroma), which are associated with chromosomal abnormalities [10].
The anomalies detectable by ultrasound in the first trimester have already been discussed. Table 2 presents the key anomalies that can be identified during the second trimester. The detection of these anomalies further refines prognostic assessment and supports multidisciplinary counseling, with TToP remaining an important option in cases of severe or complex fetal conditions.
Table 2. Major fetal anomalies detectable with ultrasound screening in the second trimester of pregnancy and their prognostic implications.

3.2. Diagnostic Testing

Diagnostic testing options such as chorionic villus sampling (CVS) and amniocentesis should be discussed and offered to all pregnant patients, particularly when confirmatory testing is desired after screening or ultrasound findings. However, these procedures carry potential risks [88].

3.2.1. Chorionic Villus Sampling

CVS, performed between 10 and 14 weeks, allows for early genetic diagnosis via fluorescence in situ hybridization (FISH), karyotyping, microarray and molecular analysis. Medical professionals perform CVS through transcervical or transabdominal procedures to extract placental tissue while using ultrasound guidance. The procedure allows for early prenatal diagnosis and provides safer and earlier pregnancy termination when needed. However, 1–2% of cases may exhibit confined placental mosaicism, which may affect fetal growth [89]. Pregnancy loss due to CVS is approximately 1 in 455 [88,90].

3.2.2. Amniocentesis

The procedure of amniocentesis, which takes place after 15 weeks, involves sampling amniotic fluid to assess genetic disorders as well as fetal infections and neural tube defects. Amniocentesis provides better detection of confined placental mosaicism than CVS. However, when performed in earlier gestations, it is associated with a higher risk of complications. The procedure carries a pregnancy loss rate of approximately 1 in 900 cases [88,90].

3.2.3. Cytogenetic Analysis

The most reliable method for detecting chromosomal abnormalities involves chromosome analysis from CVS and amniocentesis samples. The clinical use of cytogenetic testing faces certain complexities which require proper evaluation of test outcomes.
Mosaicism occurs when an individual has two or more genetically distinct cell populations. True mosaicism requires multiple independent cultures to reveal the same findings, whereas pseudomosaicism represents single-culture occurrences that usually stem from in vitro artifacts, and is generally not clinically relevant. The occurrence of confined placental mosaicism (CPM) affects about 1% to 2% of pregnancies and is restricted to placental tissue, which may lead to discrepancies between placental and fetal karyotypes [91]. This can result in false-positive cfDNA results, making amniocentesis preferable over CVS when confirmatory testing is required. In some trisomies, particularly trisomy 15, a diploid fetus may arise through trisomy rescue, which carries a risk of uniparental disomy and potential imprinting disorders (such as Prader–Willi and Angelman syndromes). Additionally, it has been observed that CVS has a slightly higher risk of cell culture failure compared to amniocentesis, though this remains rare.
A variety of cytogenetic techniques are available, each offering different levels of resolution. Karyotyping shows effectiveness in detecting large chromosomal deletions or duplications that exceed 5 million base pairs, while chromosomal microarray analysis (CMA) detects copy number variations down to 50,000 base pairs [91]. The FISH technique is used by healthcare professionals for a rapid detection of common autosomal aneuploidies and selected microdeletion syndromes (such as DiGeorge syndrome). Single-gene disorders require targeted molecular testing to confirm the presence or absence of pathogenic mutations.
Given that aneuploidy detection is the primary indication for invasive testing, FISH is often utilized as the first diagnostic test because it delivers results within 48 h without needing cell culture. Despite its diagnostic capability, FISH results should be confirmed by karyotyping due to the possibility of false positives and false negatives [92]. Microarray testing (which can be performed on uncultured cells) has become a preferred method due to its ability to detect both aneuploidy and smaller chromosomal imbalances with faster turnaround times. Additionally, the CMA test works with nonviable cells which makes it especially useful for examining fetal demise or stillbirth samples. Due to these advantages, microarray testing is now recommended as the first-line diagnostic approach for structural anomalies, along with FISH, replacing conventional karyotyping in many cases [88].
With the increasing implementation of CMA, a growing number of chromosomal variants of uncertain significance are being detected, which can contribute to parental anxiety. When a chromosomal variant of uncertain significance appears during testing, the parents usually undergo genetic evaluation to establish inheritance of the variant. A parent’s presence of the variant typically indicates it is harmless. The occurrence of chromosomal variants of uncertain significance in structurally normal pregnancies reaches 1.7%, which demonstrates the necessity of complete pre-test counseling to address potential uncertainties and guide parental decision-making [88,93].

3.2.4. Preimplantation Genetic Diagnosis (PGD)

PGD, performed after in vitro fertilization (IVF), allows healthcare providers to detect chromosomal abnormalities through polar body or blastocyst cell analysis before embryo transfer. Despite its potential, confirmatory CVS or amniocentesis is recommended due to the fact that false-negative PGD results may occur [94]. The negative predictive value of normal FISH results in PGD testing stands at 81% according to research findings [95]. While PGD has minimal risk beyond cost [88], it represents an advancing field in prenatal genetic testing.

4. Sociodemographic and Reproductive Factors Influencing TToP/VToP

It is well known that a range of socio-cultural, economic, and demographic factors influence women’s choices regarding pregnancy termination, whether due to an unplanned pregnancy or maternal health concerns. However, many studies fail to distinguish between therapeutic and elective terminations, which can yield biased conclusions about the decision-making processes for TToP. Table 3 summarizes key sociodemographic factors and their impact on abortion rates.
Table 3. Sociodemographic Determinants of Abortions.

5. Psychopathological Determinants of TToP

Various studies have examined the mental health consequences of TToP, often overlooking pre-existing mental health conditions that could affect outcomes. According to the literature data, women who have undergone TToP or VToP generally show higher levels of psychopathology before the procedure compared to those who give birth, and they often seek psychiatric help both before and after the abortion [113,114,115,116]. The majority of mental health problems appear before abortion instead of developing because of it [117]. Women with a history of psychiatric disorders (such as anxiety, mood disorders) or personality disorders are at a higher risk of undergoing abortion. Research indicates that women who underwent abortion procedures developed axis I disorders in 68.3% of cases, while this condition occurred in only 42.2% of women who did not have an abortion [118]. These women are often more likely to experience unwanted pregnancies, engage in risky behaviors, and have a greater desire for abortion due to mental health challenges and socio-economic factors.
Table 4 outlines major psychiatric determinants and their implications for pregnancy outcomes.
Table 4. Psychiatric Conditions Associated with Increased Likelihood of TToP.

6. Psychopathological Outcomes After TToP

A medically induced abortion is considered to have a high impact on a woman’s mental and reproductive health, as pregnancy termination is often a traumatic event for parents. The experience of induced abortion differs between the pregnant woman and the baby’s father, with the woman’s response influenced by her desire to give birth and the timing of the procedure [136].
According to Fergusson et al. [136], second-trimester therapeutic termination of pregnancy (TToP) has more psychological consequences and has higher prevalence of psychiatric disorders as opposed to voluntary termination of pregnancy (VToP) or miscarriage that takes place earlier in the pregnancy. Some of the possible reasons could be related to the following factors:
-
Surgical Procedure—TToP requires a surgical procedure, unlike VToP or medical management of miscarriage, contributing to a greater psychological burden [136].
-
Parental Bonding—Parents undergoing TToP may have already bonded with the fetus and adapted to the parental role, making the psychological impact greater [136].
-
Maternal–fetal Attachment—In the first trimester, the absence of fetal movement results in a weaker maternal–fetal attachment, which may lessen the emotional impact compared to TToP [136].
-
Post-abortion Distress—After TToP, parents may hold and photograph the baby, intensifying emotional distress, which is less common in VToP or miscarriage [136,137,138].
However, TToP has some positive psychological effects, especially for women who have high distress related to fetal abnormality. Research has shown that TToP can reduce pre-abortion psychological distress (especially regarding mood and anxiety symptoms). Research has shown that depressive and anxiety symptoms tend to decrease in the weeks following the procedure, with long-term mood stabilization. Careful evaluation of individual circumstances can help predict mental health outcomes and guide appropriate psychological support [138,139,140,141,142].
In this context, peri-procedural emotional support remains essential, particularly in second-trimester TToP [136]. The presence of trained staff, respectful communication and ensured privacy represent key factors that may reduce acute distress. Moreover, post-procedural follow-up should include psychological evaluation, especially in patients with identified risk factors (e.g., pre-existing psychiatric disorders, limited social support, or coercion Grief counseling, mental health referral and contraceptive counseling are recommended to reduce long-term psychological morbidity and prevent repeat unintended pregnancies. Counseling and psychological support during the peri- and post-procedural phases of TToP should be considered integral components of standard care [105,139,143,144,145,146,147].
Table 5 presents the most common mental health outcomes and associated risk factors.
Table 5. Psychological Outcomes Following TToP.
A wide range of factors can shape the psychological aftermath of a therapeutic abortion. Table 6 details individual, social and clinical elements that may predict adverse outcomes.
Table 6. Risk Factors for Negative Psychological Outcomes after TToP.

7. Medical and Surgical Methods of TToP/VToP

It is known that termination of pregnancy can be performed via two primary approaches: medical (pharmacologic) and surgical (instrumental or aspiration). The choice depends on gestational age, clinical indications, patient preference, and local legal and resource constraints [156,157,158]. Both medical and surgical abortion methods are safe and effective when performed according to evidence-based guidelines.

7.1. Pre-Abortion Evaluation

A thorough pre-abortion evaluation is required before initiating any abortion method. This step typically consists of the following: medical history, allergy assessment, confirmation of gestational age (by last menstrual period or ultrasound), pelvic ultrasound to confirm intrauterine pregnancy, and specific laboratory tests (e.g., complete blood count, Rh status, glucose levels in diabetic patients, coagulation profile if anticoagulants are being taken) [159,160]. Patients are counseled regarding options, risks and follow-up. Informed consent is essential.
In addition to medical evaluation, well-structured pre-procedural counseling is necessary and should be considered an essential component of care. This includes providing clear information regarding diagnosis, prognosis, available options (continuation of pregnancy versus TToP), as well as potential physical and psychological outcomes. Psychological assessment usually consists of identifying pre-existing psychiatric conditions, levels of distress, decisional conflict and social support. When necessary, it is recommended to refer to a mental health professional or genetic counselor [102,117,118,136,148,149].

7.2. Medical Abortion

Medical abortion is recommended up to 11 weeks of gestation. It may be performed at home or in clinical settings. It is non-invasive and is considered to provide a greater sense of privacy and autonomy [161,162,163]. The preferred regimen for medical abortion is mifepristone followed by misoprostol, while methotrexate is used rarely. The standard protocol includes administration of mifepristone (taken as a single 200 mg oral tablet, typically on Day 1) followed by misoprostol, which is administered 24–48 h later in one of the following routes:
-
Buccal: Four 200 mcg tablets placed between the cheek and gum for 30 min, then swallowed.
-
Vaginal: Four 200 mcg tablets inserted into the vagina 6 to 48 h after mifepristone.
-
Sublingual: Two to four 200 mcg tablets are placed under the tongue for 30 min [161,162,163].
According to the NAF 2020 guidelines, if the patient is more than 63 days from the last menstrual period (LMP), a second dose of 800 mcg misoprostol can be administered four hours after the first dose. For pregnancies beyond 70 days, the second dose of misoprostol is recommended four hours after the administration of mifepristone [161,162,163].
NSAIDs are typically sufficient for pain management during medical abortion at home; routine opioid prescription is not necessary, but a short course may be offered when NSAIDs are contraindicated or not tolerated [164]. The use of prophylactic antibiotics is usually not recommended. Contraceptive counseling can be offered during follow-up, depending on the patient’s interest.
Patients must be advised to contact their healthcare provider [161,165] if they experience the following:
-
Excessive bleeding (e.g., soaking two or more pads in two consecutive hours).
-
Severe pain that is unresponsive to analgesics.
-
Fever > 38 °C (100.4 °F) that lasts for more than 24 h after misoprostol.
-
No bleeding within 24 h of misoprostol administration.
-
Persistent nausea, vomiting, diarrhea, or abdominal pain beyond 24 h.
Follow-up to confirm abortion success does not always require ultrasound. According to the NAF 2020 guidelines, clinical history and home pregnancy tests may be sufficient [166]. Alternatively, quantitative hCG testing can be performed: it is considered that a decrease of ≥50% by 72 h, ≥60% by 4–5 days, and ≥80% by day 7 from mifepristone administration is consistent with successful abortion [167,168]. Ultrasound remains a valid option for confirming expulsion by demonstrating the absence of a gestational sac or embryo.
In rare cases, a regimen using methotrexate and misoprostol may be employed [161,162,163]. The evidence-based protocol includes oral or intramuscular methotrexate followed three to five days later by vaginal misoprostol for gestational ages up to 63 days.
Contraindications to medical abortion include the following: the presence of an intrauterine device (IUD, which should be removed prior to the procedure); known allergy to mifepristone or misoprostol; and chronic adrenal insufficiency (particularly in patients undergoing long-term systemic corticosteroid therapy). Other medical conditions that preclude medication abortion include suspected or confirmed ectopic pregnancy, hemorrhagic disorders, anticoagulant therapy (excluding low-dose aspirin), hemodynamic instability, and inherited porphyria. On the other hand, conditions such as anemia, seizure disorders, asthma managed with steroid inhalers, obesity, breastfeeding, HIV/AIDS and other sexually transmitted infections are not considered contraindications [161].
Complications of medical abortion may occur despite high safety and efficacy rates, particularly when gestational age is underestimated or patient selection criteria are not strictly followed. Management strategies must be timely and based on clinical presentation [161,165]. Table 7 describes the complications of medical abortion and the therapeutic interventions required for them.
Table 7. Common complications of medical abortion and recommended clinical management.

7.3. Surgical or Aspiration Abortion

Surgical abortion is typically used up to 16 weeks via manual or electric vacuum aspiration. After 16 weeks, dilation and evacuation (D&E) is indicated and must be performed by experienced clinicians. Aspiration is brief (5–10 min) and performed in a clinic or hospital under local anesthesia, with or without sedation [171].
Instrument kits may include manual vacuum aspirator, cannula, syringe, tenaculum, speculum, cervical dilators, forceps and gauze. In D&E procedures, additional specialized tools and real-time ultrasound guidance are essential in order to ensure safety and effectiveness. In cases of advanced gestation, induced fetal demise may be required before the procedure [172,173].
Steps include bimanual examination, cervical dilation with mechanical or pharmacological agents—such as misoprostol or osmotic dilators (e.g., Dilapan, laminaria)—antiseptic cervical preparation, insertion of the cannula, and aspiration of uterine contents. Osmotic dilators may be placed in the cervix in advance to ensure adequate dilation, particularly in second-trimester procedures. Misoprostol and mifepristone can also aid in cervical ripening. If molar pregnancy is suspected, the aspirated tissue should be sent to pathology for histological confirmation [172,173].
Ultrasound may be employed during or after the procedure to verify completion. Uterotonics are routinely used to manage uterine tone and minimize bleeding (both intra- and post-procedurally). Prophylactic antibiotics are usually administered to reduce the risk of post-procedural infections [174,175]. A summary of complications and management strategies for aspiration abortion is provided in Table 8.
Table 8. Common complications of aspiration abortion and recommended clinical management.

8. The EUROCAT Network

Congenital anomalies are a leading cause of infant mortality and morbidity worldwide. The EUROCAT network, established in 1979, monitors these anomalies across 21 countries, covering approximately a quarter of Europe’s birth population. Since 2015, its Central Registry has been managed by the European Commission’s Joint Research Center (JRC) as part of the European Platform on Rare Disease Registration. With data from over 1.1 million births annually, EUROCAT collects epidemiological information, identifies teratogenic risks and evaluates prevention measures [176,177,178].
Each year, the JRC-EUROCAT Central Registry analyzes data from live births, fetal deaths (≥20 weeks gestation) and terminations of pregnancy for fetal anomalies (TOPFA). This allows for trend monitoring and the detection of temporal clusters (which may indicate teratogenic exposures). When unusual case clusters are identified, local registries conduct investigations and notify public health authorities for timely intervention [176,177,179,180].
The pan-European trend analysis monitors prevalence rates for 94 congenital anomaly subgroups, particularly those with insufficient case numbers for local-level evaluation. For the 2013–2022 period, the following trends were identified:

8.1. Increasing Trends Identified at Pan-European Level

EUROCAT surveillance has revealed several congenital anomalies with rising prevalence over the past decade. Table 9 highlights those conditions and discusses potential contributing factors.
Table 9. EUROCAT-Reported Congenital Anomalies with Increasing Prevalence (2013–2022).
While these trends may be partially explained by advances in prenatal diagnostics and changes in coding practices, maternal factors (such as obesity or maternal diabetes) may also contribute. Each condition is described below with clinical details and its potential implications for therapeutic abortion decisions.
Double-Outlet Right Ventricle (DORV)—DORV is described in the literature as a serious congenital heart defect in which both the aorta and pulmonary artery arise from the right ventricle [185]. This condition is usually diagnosed early. While some infants may initially be asymptomatic, corrective surgery is often required within the first year of life. In severe cases where surgical intervention is not successful or where significant complications arise (such as severe cyanosis or heart failure), therapeutic abortion may be considered. The rate of survival with early surgery is considered to be high. On the other hand, if DORV is left untreated, the severity of the disease can lead to a poor quality of life, making abortion a potential option when no corrective measures are available.
Caudal Regression Sequence (CRS)—CRS, a rare and severe defect of the sacrum and lumbar spine, is often linked to maternal pre-gestational diabetes. This condition can result in major disabilities, such as paralysis, bowel and bladder dysfunction and a limited lifespan [186,187]. In severe cases, where the child may be born with a severe form of malformed spine as well as potential associated anomalies (e.g., renal malformations, absence of lower limbs), therapeutic abortion is often considered due to extreme disabilities and poor prognosis. CRS cases diagnosed early in pregnancy offer an opportunity for parents to consider the potential long-term suffering and the available options for care.
Patau Syndrome (Trisomy 13) and Edward’s Syndrome (Trisomy 18)—Both Patau Syndrome and Edward’s Syndrome are chromosomal disorders that result in severe intellectual disabilities, profound developmental delays and early death (often within the first year of life) [188,189,190]. These conditions generally lead to death in infancy, and the decision for therapeutic abortion is often made early in pregnancy based on the diagnosis (as these syndromes have no effective treatment options and are associated with immense suffering for the child). For some parents, abortion is seen as a relevant choice given the certainty of a very short and painful life for the infant.

8.2. Decreasing Trends Identified at Pan-European Level

Some congenital conditions have shown a declining trend across Europe. Table 10 outlines congenital anomalies for which a declining prevalence has been reported and discusses possible explanations for these observed trends.
Table 10. EUROCAT-Reported Congenital Anomalies with Decreasing Prevalence (2013–2022).
Therefore, some of these trends are considered to be attributable to improved prenatal care, diagnostic accuracy or classification practices. However, further investigation is necessary to fully understand these trends. A brief overview of each condition and its relevance to TToP is discussed below.
Hydrocephaly—Hydrocephaly involves an accumulation of cerebrospinal fluid in the brain. This condition can lead to an increase in intracranial pressure and potential damage to brain tissue. Mild cases of hydrocephaly can often be managed with shunting, but more severe forms may lead to developmental delays, seizures and poor long-term prognosis. In cases where hydrocephaly is diagnosed in conjunction with other severe malformations (e.g., agenesis of the corpus callosum, severe developmental delay), the severity of the condition may lead the mother to take into consideration the therapeutic abortion as a valid solution [194,195]. Early detection allows for a decision to be made sooner in the pregnancy in order to prevent potential long-term suffering for the child, but also for the family.
Severe Microcephaly—Severe Microcephaly is defined as a head circumference more than 3 standard deviations below the mean for sex and gestational age. It is often associated with intellectual disability as well as other neurological deficits. This condition can be extremely debilitating (developmental delays, seizures and neurological impairments). Some children may survive and reach adulthood, but their quality of life is usually greatly affected [196]. In cases where microcephaly is diagnosed early in pregnancy (especially when associated with other neurological malformations), the severity of the condition may lead the mother to seek therapeutic abortion. A poor prognosis, as well as no viable treatment options to improve quality of life, represent factors that may lead the mother to choose TToP.
Anophthalmos—Anophthalmos is the congenital absence of one or both eyes, resulting in blindness. This birth defect does not necessarily affect life expectancy, but it may be associated with other serious anomalies (such as brain malformations or developmental delays). Therapeutic abortion may be considered in cases where anophthalmos is part of a broader syndrome with a poor prognosis or severe developmental delay. However, the mother may prefer to continue the pregnancy if the fetus has isolated anophthalmos (particularly if diagnosed early in pregnancy), as long-term management options such as prosthetic eyes or early interventions may improve the quality of life [197].
Congenital glaucoma—This condition is characterized by elevated intraocular pressure and is usually diagnosed in infancy. It is well known that congenital glaucoma can lead to blindness. In severe cases where blindness occurs (especially when associated with other syndromes), therapeutic abortion may be considered. On the other hand, if interventions (e.g., surgery or medication to control intraocular pressure) are performed early, many children with isolated congenital glaucoma can have functional vision [198].
Atrial septal defect (ASD)—Atrial septal defect is characterized by a hole in the wall that separates the two atria of the heart, allowing abnormal blood flow between the heart’s chambers. Most cases of ASD are asymptomatic or can be successfully managed with surgery in childhood, with excellent long-term outcomes. Isolated ASD is not in itself a standard indication for therapeutic termination of pregnancy. However, it may enter counseling discussions when the defect is large, deemed unsuitable for effective surgical repair, or when it occurs in association with severe syndromic or multisystem disease that significantly worsens the overall prognosis [199].
Tricuspid atresia and stenosis—Tricuspid atresia and stenosis are congenital heart defects that affect the tricuspid valve and right ventricle [200]. Therapeutic abortion might be considered in severe cases where surgical repair is not possible, due to the high risk of death early in life [201]. However, with advanced surgical techniques and early intervention, many children with these conditions can survive and can live relatively normal lives.
Cleft palate—Cleft palate is a defect in the soft and/or hard palate that can cause difficulty with feeding, speech and hearing and typically requires one or more surgeries for correction [202]. In the vast majority of cases, cleft palate can be successfully repaired with surgery, and children go on to live normal lives. Accordingly, isolated cleft palate is not in itself a typical indication for therapeutic termination of pregnancy. However, it may enter counseling discussions when it occurs as part of a severe syndrome [203] or when the malformation leads to life-threatening conditions (e.g., severe airway obstruction refractory to postnatal intervention) or when associated with major neurological or skeletal impairment.
Gastroschisis—Gastroschisis involves the protrusion of abdominal contents through a defect in the abdominal wall. It is typically seen in the offspring of younger mothers. This condition is usually treatable through surgical intervention shortly after birth, with good survival in isolated cases, but in some cases, it can be associated with other serious anomalies or prematurity that might complicate recovery [203]. In this context, gastroschisis is not in itself a standard indication for therapeutic termination of pregnancy, but it may enter counseling discussions when associated with severe syndromic or multisystem disease that significantly worsens the overall prognosis.
Hypospadias—Hypospadias is a condition in boys where the urethral opening is abnormally located on the underside of the penis. This condition often requires surgery for correction [204]. Most cases have a favorable long-term outcome and do not lead to life-threatening complications. Accordingly, hypospadias on its own is not a typical indication for therapeutic termination of pregnancy, but it may enter counseling discussions when it forms part of a broader syndrome or multisystem disorder with major implications for survival or long-term quality of life.
Pierre Robin sequence—Pierre Robin sequence is characterized by micrognathia, glossoptosis and airway obstruction. It is often associated with a posterior cleft palate. Most children with Pierre Robin sequence can be managed with timely airway and feeding interventions, and the cleft palate can usually be surgically corrected later in childhood, so isolated cases generally have a heterogeneous but often compatible prognosis. From the perspective of therapeutic termination of pregnancy, these anomalies may enter counseling discussions mainly when there is severe airway compromise anticipated despite optimal postnatal care, or when they occur in the context of a severe syndromic or multisystem condition (for example, with major neurological and/or skeletal malformations) that leads to a clearly poor prognosis [205].
Skeletal dysplasias—Skeletal dysplasias are genetic disorders characterized by abnormal bone development. Some forms of skeletal dysplasia can lead to severe deformities or reduced life expectancy [206]. Therefore, therapeutic abortion may be considered in extreme cases (where the prognosis is poor). On the other hand, less severe forms of skeletal dysplasias often allow for a normal lifespan.

10. Conclusions

The therapeutic termination of pregnancy (TToP) represents a crucial element of modern reproductive healthcare because it provides a medically supervised choice when maternal health is endangered or when severe fetal abnormalities are detected. The availability of advanced prenatal screening and diagnostic tools including serum markers, ultrasound, cell-free DNA testing, chorionic villus sampling and amniocentesis has greatly improved the ability to detect conditions early, supporting better decision-making. The methods enable doctors to determine risks with high accuracy and perform pregnancy terminations (medical or aspiration/surgical abortions) at safer times. However, the decision to pursue TToP is rarely based on medical findings alone. First-trimester combined screening (nuchal translucency measurement together with serum markers such as PAPP-A and free beta-hCG) provides early risk stratification, while cell-free fetal DNA testing offers high sensitivity for common aneuploidies (trisomy 21, 18 and 13). Invasive procedures, such as chorionic villus sampling and amniocentesis, remain the gold standard for definitive chromosomal diagnosis. Preimplantation genetic diagnosis further extends these options for couples undergoing in vitro fertilization. Genetic counseling plays a central role in this process, as it ensures that patients receive detailed information about the risks, benefits and limitations of each test, thereby supporting truly informed reproductive decisions.
The rates of abortion and access to abortion services vary considerably based on sociodemographic factors such as age, marital status, educational attainment, employment and urban versus rural residence. Cultural stigmas, limited access to contraception and legal restrictions, are factors that increase the incidence of unsafe procedures. Younger women, students and individuals who do not have an adequate financial or family support experience heightened vulnerability. Immigrant women and ethnic minorities face disproportionately higher abortion rates due to economic hardship and systemic barriers to healthcare access. Intimate partner violence and gender-based violence further contribute to unwanted pregnancies and repeated abortions. Religious beliefs also play a dual role: while strong religious affiliations may reduce the likelihood of seeking abortion, they can also intensify feelings of guilt and psychological distress in women who do undergo the procedure. Women with pre-existing psychiatric conditions (such as anxiety, affective disorders, psychotic or trauma-related disorders) have higher rates of therapeutic abortion. Notably, the majority of mental health problems appear before the procedure rather than developing as a consequence of it. Women with borderline personality disorder, substance use disorders, eating disorders and childhood psychiatric disorders (such as ADHD and conduct disorder) are at particular risk of unplanned pregnancies and subsequent termination. The procedure leads to emotional relief for most patients, but some women develop lasting symptoms which include depression, anxiety, PTSD and substance misuse. Second-trimester TToP carries a greater psychological burden compared to first-trimester procedures, largely due to stronger maternal-fetal attachment and the surgical nature of the intervention. Risk factors for adverse psychological outcomes include coercion, pre-existing psychopathology, limited social support, strong maternal–fetal attachment and the absence of contraceptive use prior to pregnancy. Emotional and social support is a major protective factor. On the other hand, its absence can intensify feelings of guilt, grief and psychological distress.
The legal, ethical and religious frameworks regarding TToP vary widely across countries, but consistently shape access and perception. The ethical debate fundamentally revolves around the tension between the fetus’s right to life and the woman’s right to bodily autonomy. While 61 countries (representing 39.5% of the global population) currently allow abortion upon request within a specified period, 66 countries prohibit it except when the mother’s life is at risk. In Romania, voluntary termination of pregnancy is legal up to 14 weeks of gestation, and therapeutic abortion beyond this limit is permitted only for medical reasons with no explicit gestational ceiling, though clinical guidelines typically consider up to 24 weeks. Laws that restrict abortion do not lower the number of abortions, but rather force women to seek dangerous procedures that increase their health risk. According to the World Health Organization, an estimated 45% of all induced abortions worldwide are unsafe, corresponding to approximately 25 million unsafe procedures per year. Unsafe abortions, predominantly occurring in developing countries, remain a major and preventable contributor to maternal morbidity and mortality.
Between 2013 and 2022, EUROCAT reported increasing trends for conditions such as Double Outlet Right Ventricle (DORV), Caudal Regression Sequence (CRS), Trisomy 13 and Trisomy 18, which represent severe anomalies that may lead to therapeutic termination of pregnancy. The increase in DORV cases is considered to be due to improved coding, while CRS has been linked to higher rates of maternal diabetes and obesity. The increasing trends for Trisomy 13 and 18 are associated with a better access to non-invasive prenatal testing. In contrast, conditions like hydrocephaly, severe microcephaly, anophthalmos, congenital glaucoma and atrial septal defect showed decreasing trends. This finding may be attributed to improvements in terms of prenatal care, better classification or earlier detection (which in turn may influence TToP decisions in severe cases). Conversely, decreasing trends were observed for conditions such as gastroschisis, hypospadias, cleft palate, Pierre Robin sequence, skeletal dysplasias, tricuspid atresia and stenosis, congenital glaucoma and atrial septal defect. These declines are likely attributable to improvements in prenatal care, more accurate classification systems and earlier detection, although the precise mechanisms underlying some of these trends warrant further investigation. It should be noted that many of the conditions with decreasing prevalence (such as isolated cleft palate, hypospadias, gastroschisis and atrial septal defect) are not in themselves standard indications for TToP, but may enter counseling discussions when they occur in the context of severe syndromic or multisystem disease.
The management of TToP should not be limited to clinical practice, but should also include psychological support, ethical reflection and social awareness. Peri-procedural emotional support is essential, particularly in second-trimester TToP, and should involve trained staff, respectful communication and ensured privacy to reduce acute distress. Post-procedural follow-up should include systematic psychological evaluation, especially in patients with identified risk factors (e.g., pre-existing psychiatric disorders, limited social support or coercion). Grief counseling and mental health referral are recommended as integral components of standard care to reduce long-term psychological morbidity. Contraceptive counseling is necessary in order to prevent repeated abortion procedures. Mental health services are recommended to ensure the long-term well-being of the mother.
In conclusion, TToP is more than just a medical act; it is a complex, deeply human decision. The findings of this review reinforce the importance of a multidisciplinary, evi-dence-informed approach that integrates clinical expertise, psychological support, ethical reflection and legal awareness. Ensuring safe, equitable and compassionate access to TToP, regardless of socio-economic background, geographic location or cultural context, remains a critical component of reproductive healthcare. Future research should focus on standardizing psychological screening protocols for women undergoing TToP, evaluating the long-term mental health outcomes through prospective longitudinal studies and addressing the persistent disparities in access to safe abortion services across different regions and populations.

Author Contributions

Conceptualization, L.P. and R.-M.S.; methodology, M.-O.P.; formal analysis, M.-M.M.; investigation, M.-D.D.; resources, G.-P.G.; data curation, A.-A.C.; writing—original draft preparation, M.-D.D.; writing—review and editing, F.-E.A.; visualization, A.-S.D.; supervision, R.-M.S.; project administration, L.P. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study.

Acknowledgments

Publication of this paper was supported by the University of Medicine and Pharmacy “Carol Davila” through the institutional program Publish not Perish.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
ADHDAttention-deficit/hyperactivity disorder
AFPAlpha-fetoprotein
ANAnorexia nervosa
ARPKDAutosomal recessive polycystic kidney disease
AVSDAtrioventricular septal defect
BNBulimia nervosa
BPDBorderline personality disorder
bpmBeats per minute
CAsCongenital anomalies
CDHCongenital diaphragmatic hernia
cfDNACell-free fetal DNA
CMAChromosomal microarray analysis
CVSChorionic villus sampling
DVDuctus venosus
FISHFluorescence in situ hybridization
hCGHuman chorionic gonadotropin
HLHSHypoplastic left heart syndrome
IPVIntimate partner violence
IVFIn vitro fertilization
NIPSNon-invasive prenatal screening
NTNuchal translucency
PGDPreimplantation genetic diagnosis
PPVPositive predictive value
PTSDPost-traumatic stress disorder
STDsSexually transmitted diseases
TToPTherapeutic termination of pregnancy
VToPVoluntary termination of pregnancy
X-raysX-radiation

References

  1. Berer, M. Abortion Law and Policy Around the World: In Search of Decriminalization. Health Hum. Rights 2017, 19, 13–27. [Google Scholar] [PubMed] [PubMed Central]
  2. Center for Reproductive Rights. The World’s Abortion Laws, 2023 (Version 3). Available online: https://reproductiverights.org/wp-content/uploads/2025/10/WALM_2023-v3-Updated_12-20-23.pdf (accessed on 2 March 2026).
  3. Di Lorenzo, P.; Casella, C.; Marisei, M.; Sarno, L.; Aquino, C.I.; Osuna, E.; Guida, M.; Niola, M. A COVID Dilemma: How to Manage Pregnancies in Case of Severe Respiratory Failure? Healthcare 2023, 11, 486. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  4. Sekkarie, A.; Woodruff, R.; Whitaker, M.; Kramer, M.R.; Zapata, L.B.; Ellington, S.R.; Meaney-Delman, D.M.; Pham, H.; Patel, K.; Taylor, C.A.; et al. COVID-19-Associated Hospitalization Surveillance Network COVID-NETSurveillance Team Characteristics treatment of hospitalized pregnant women with COVID-19. Am. J. Obstet. Gynecol. MFM 2022, 4, 100715. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  5. Budi, D.S.; Pratama, N.R.; Wafa, I.A.; Putra, M.; Wardhana, M.P.; Wungu, C.D.K. Remdesivir for pregnancy: A systematic review of antiviral therapy for COVID-19. Heliyon 2022, 8, e08835. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  6. Penchaszadeh, V.B. Preventing congenital anomalies in developing countries. Public Health Genom. 2002, 5, 61–69. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  7. Godwin, K.A.; Sibbald, B.; Bedard, T.; Kuzeljevic, B.; Lowry, R.B.; Arbour, L. Changes in frequencies of select congenital anomalies since the onset of folic acid fortification in a Canadian birth defect registry. Can. J. Public. Health. 2008, 99, 271–275. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  8. El Koumi, M.A.; Al Banna, E.A.; Lebda, I. Pattern of congenital anomalies in newborn: A hospital-based study. Pediatr. Rep. 2013, 5, e5. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  9. Kochanek, K.D.; Kirmeyer, S.E.; Martin, J.A.; Strobino, D.M.; Guyer, B. Annual summary of vital statistics: 2009. Pediatrics 2012, 129, 338–348. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  10. American College of Obstetricians and Gynecologists. Practice Bulletin No. 163: Screening for Fetal Aneuploidy. Obstet. Gynecol. 2016, 127, e123–e137. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  11. Neumann, P.E.; Frankel, W.N.; Letts, V.A.; Coffin, J.M.; Copp, A.J.; Bernfield, M. Multifactorial inheritance of neural tube defects: Localization of the major gene and recognition of modifiers in ct mutant mice. Nat. Genet. 1994, 6, 357–362. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  12. Shaw, G.M.; Quach, T.; Nelson, V.; Carmichael, S.L.; Schaffer, D.M.; Selvin, S.; Yang, W. Neural tube defects associated with maternal periconceptional dietary intake of simple sugars and glycemic index. Am. J. Clin. Nutr. 2003, 78, 972–978. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  13. Graham, T.P., Jr.; Driscoll, D.J.; Gersony, W.M.; Newburger, J.W.; Rocchini, A.; Towbin, J.A. Task Force 2: Congenital heart disease. J. Am. Coll. Cardiol. 2005, 45, 1326–1333. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  14. Adzick, N.S.; Thom, E.A.; Spong, C.Y.; Brock, J.W., 3rd; Burrows, P.K.; Johnson, M.P.; Howell, L.J.; Farrell, J.A.; Dabrowiak, M.E.; Sutton, L.N.; et al. MOMS Investigators. A randomized trial of prenatal versus postnatal repair of myelomeningocele. N. Engl. J. Med. 2011, 364, 993–1004. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  15. Nicolaides, K.H.; Azar, G.; Byrne, D.; Mansur, C.; Marks, K. Fetal nuchal translucency: Ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ 1992, 304, 867–869. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  16. Baer, R.J.; Norton, M.E.; Shaw, G.M.; Flessel, M.C.; Goldman, S.; Currier, R.J.; Jelliffe-Pawlowski, L.L. Risk of selected structural abnormalities in infants after increased nuchal translucency measurement. Am. J. Obstet. Gynecol. 2014, 211, e1–e19. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  17. Evans, M.I.; Krantz, D.A.; Hallahan, T.W.; Sherwin, J. Impact of nuchal translucency credentialing by the FMF, the NTQR or both on screening distributions and performance. Ultrasound Obstet. Gynecol. 2012, 39, 181–184. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  18. Malone, F.D.; Canick, J.A.; Ball, R.H.; Nyberg, D.A.; Comstock, C.H.; Bukowski, R.; Berkowitz, R.L.; Gross, S.J.; Dugoff, L.; Craigo, S.D.; et al. First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down’s syndrome. N. Engl. J. Med. 2005, 353, 2001–2011. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  19. Martins Santana, E.F.; Araujo Júnior, E.; Tonni, G.; Costa, F.D.S.; Meagher, S. Acrania-exencephaly-anencephaly sequence phenotypic characterization using two- and three-dimensional ultrasound between 11 and 13 weeks and 6 days of gestation. J. Ultrason. 2018, 18, 240–246. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  20. Kousa, Y.A.; du Plessis, A.J.; Vezina, G. Prenatal diagnosis of holoprosencephaly. Am. J. Med. Genet. C Semin. Med. Genet. 2018, 178, 206–213. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  21. Correa, G.G.; Amaral, L.F.; Vedolin, L.M. Neuroimaging of Dandy-Walker malformation: New concepts. Top. Magn. Reson. Imaging 2011, 22, 303–312. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  22. Ungureanu, D.R.; Comănescu, M.C.; Istrate-Ofiţeru, A.M.; Zorilă, G.L.; Drăgușin, R.C.; Iliescu, D.G. Open Spina Bifida: The Role of Ultrasound Markers in the First Trimester and Morphopathology Correlation. Curr. Health Sci. J. 2023, 49, 445–456. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  23. Trudell, A.S.; Odibo, A.O. Diagnosis of spina bifida on ultrasound: Always termination? Best Pract. Res. Clin. Obstet. Gynaecol. 2014, 28, 367–377. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  24. Ong, A.G.J.; Rolnik, D.L.; Menezes, M.; Meagher, S. Early Diagnosis and Differences in Progression of Fetal Encephalocele. J. Ultrasound Med. 2020, 39, 1435–1440. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  25. Alluhaybi, A.A.; Altuhaini, K.; Ahmad, M. Fetal Ventriculomegaly: A Review of Literature. Cureus 2022, 14, e22352. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  26. Geraldini, F.; De Cassai, A.; Ciccarino, P.; Calabrese, F.; Chioffi, F.; Munari, M. Ultrasound as a Useful Tool in Hydrocephalus Management During Pregnancy: A Case Report. A&A Pract. 2021, 15, e01451. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  27. Yıldırım, G.; Gungorduk, K.; Yazıcıoğlu, F.; Gul, A.; Cakar, F.; Celikkol, O.; Ceylan, Y. Prenatal diagnosis of complete atrioventricular septal defect: Perinatal and neonatal outcomes. Obstet. Gynecol. Int. 2009, 2009, 958496. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  28. ter Heide, H.; Thomson, J.D.; Wharton, G.A.; Gibbs, J.L. Poor sensitivity of routine fetal anomaly ultrasound screening for antenatal detection of atrioventricular septal defect. Heart 2004, 90, 916–917. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  29. Srisupundit, K.; Luewan, S.; Tongsong, T. Prenatal Diagnosis of Fetal Heart Failure. Diagnostics 2023, 13, 779. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  30. Shenker, L.; Reed, K.L.; Anderson, C.F.; Kern, W. Fetal pericardial effusion. Am. J. Obstet. Gynecol. 1989, 160, 1505–1507. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  31. Teixeira, S.; Guedes-Martins, L. First Trimester Tricuspid Regurgitation: Clinical Significance. Curr. Cardiol. Rev. 2023, 19, e061222211643. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  32. Braga, M.; Moleiro, M.L.; Guedes-Martins, L. Clinical Significance of Ductus Venosus Waveform as Generated by Pressure- volume Changes in the Fetal Heart. Curr. Cardiol. Rev. 2019, 15, 167–176. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  33. Li, S.; Wu, H.; Zhu, L.; Li, Q.; Dong, X. Reference values of normal fetal ductus venosus Doppler flow measurements at 11–14 weeks of gestation. PLoS ONE 2024, 19, e0312874. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  34. Valenti, O.; Di Prima, F.A.; Renda, E.; Faraci, M.; Hyseni, E.; De Domenico, R.; Monte, S.; Giorgio, E. Fetal cardiac function during the first trimester of pregnancy. J. Prenat. Med. 2011, 5, 59–62. [Google Scholar] [PubMed] [PubMed Central]
  35. Bravo-Valenzuela, N.J.; Rocha, L.A.; Machado Nardozza, L.M.; Araujo Júnior, E. Fetal cardiac arrhythmias: Current evidence. Ann Pediatr Cardiol. 2018, 11, 148–163, Erratum in Ann. Pediatr. Cardiol. 2018, 11, 332. https://doi.org/10.4103/0974-2069.240856. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  36. Tonni, G.; Sepulveda, W. Cleft Lip and Cleft Palate: Time to Include Orofacial Ultrasound Markers into the First-Trimester Anatomy Scan? J. Ultrasound Med. 2023, 42, 2905–2909. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  37. Li, H.; Yao, Y.; Zhang, C.; Qin, Y.; Zeng, L.; Song, J.; Lu, L.; Wang, W.; Liu, L. Prenatal diagnosis and outcomes in 320 fetuses with nasal bone anomalies. Front. Genet. 2023, 14, 1170720. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  38. Daskalakis, G.; Anastasakis, E.; Souka, A.; Manoli, A.; Koumpis, C.; Antsaklis, A. First trimester ultrasound diagnosis of congenital diaphragmatic hernia. J. Obstet. Gynaecol. Res. 2007, 33, 870–872. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  39. Sepulveda, W.; Wong, A.E.; Casasbuenas, A.; Solari, A.; Alcalde, J.L. Congenital diaphragmatic hernia in a first-trimester ultrasound aneuploidy screening program. Prenat. Diagn. 2008, 28, 531–534. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  40. Yang, Y.; Wang, H.; Wang, Z.; Pan, X.; Chen, Y. First trimester diagnosis of body stalk anomaly complicated by ectopia cordis. J. Int. Med. Res. 2020, 48, 300060520980210. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  41. Protrka, Z.; Dimitrijevic, A.; Kastratovic, T.; Djuric, J.; Arsenijevic, P.; Novakovic, T.; Milosavljevic, M. Prenatally diagnosed fetal omphalocele at 11 week gestation—A case report. Cent. Eur. J. Med. 2013, 8, 431–433. [Google Scholar] [CrossRef] [Scilit]
  42. Pontes, K.F.M.; Muniz, T.D.; Caldas, J.V.J.; Acácio, G.L.; Lapa, D.A.; Rolo, L.C.; Araujo, E., Jr. Fetal Gastroschisis: Review from Diagnosis to Delivery. J. Clin. Ultrasound 2025, 53, 1122–1130. [Google Scholar] [CrossRef] [Scilit]
  43. Lesieur, E.; Barrois, M.; Bourdon, M.; Blanc, J.; Loeuillet, L.; Delteil, C.; Torrents, J.; Bretelle, F.; Grangé, G.; Tsatsaris, V.; et al. Megacystis in the first trimester of pregnancy: Prognostic factors and perinatal outcomes. PLoS ONE 2021, 16, e0255890. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  44. Mastromoro, G.; Guadagnolo, D.; De Luca, A.; Rongioletti, M.C.A.; Pizzuti, A. Fetal Hydrops: Genetic Dissection of an Unspecific Sonographic Finding—A Comprehensive Review. Diagnostics 2025, 15, 465. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  45. Krakow, D.; Lachman, R.S.; Rimoin, D.L. Guidelines for the prenatal diagnosis of fetal skeletal dysplasias. Genet. Med. 2009, 11, 127–133. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  46. Clementschitsch, G.; Hasenöhrl, G.; Steiner, H.; Staudach, A. Early Diagnosis of a Fetal Skeletal Dysplasia Associated with Increased Nuchal Translucency with 2D and 3D Ultrasound. Ultraschall Med. 2003, 24, 349–352. (In German) [Google Scholar] [CrossRef] [Scilit] [PubMed]
  47. Liao, Y.M.; Li, S.L.; Luo, G.Y.; Wen, H.X.; Ouyang, S.Y.; Chen, C.Y.; Yao, Y.; Bi, J.R.; Tian, X.X. Routine screening for fetal limb abnormalities in the first trimester. Prenat. Diagn. 2016, 36, 117–126. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  48. Niu, Z.; Meng, H.; Zhang, X.; Ouyang, Y.; Zhang, Y.; Wu, X. Two case reports: Early detection of amniotic band syndrome by adhesion between hand and umbilical cord at 11 to 14 weeks’ gestation. Medicine 2019, 98, e18302. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  49. Stuurman, K.E.; van der Mespel-Brouwer, M.H.; Engels, M.A.J.; Elting, M.W.; Bhola, S.L.; Meijers-Heijboer, H. Isolated Increased Nuchal Translucency in First Trimester Ultrasound Scan: Diagnostic Yield of Prenatal Microarray and Outcome of Pregnancy. Front. Med. 2021, 8, 737936. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  50. Fantasia, I.; Catagini, S.; Zamagni, G.; Greco, P.; Bianchini, I.; Bussolaro, S.; Quadrifoglio, M.; Lo Bello, L.; Monasta, L.; Ricci, G.; et al. The clinical impact of the first-trimester nuchal translucency between the 95th–99th percentiles. Prenat. Diagn. 2023, 43, 929–936. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  51. Martínez-Payo, C.; Cabezas, E.; Nieto, Y.; Ruiz de Azúa, M.; García-Benasach, F.; Iglesias, E. Detection of single umbilical artery in the first trimester ultrasound: Its value as a marker of fetal malformation. Biomed. Res. Int. 2014, 2014, 548729. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  52. Conde-Agudelo, A.; Kafury-Goeta, A.C. Triple-marker test as screening for Down syndrome: A meta-analysis. Obstet. Gynecol. Surv. 1998, 53, 369–376. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  53. Palomaki, G.E.; Neveux, L.M.; Knight, G.J.; Haddow, J.E.; Pandian, R. Maternal serum invasive trophoblast antigen (hyperglycosylated hCG) as a screening marker for Down syndrome during the second trimester. Clin. Chem. 2004, 50, 1804–1808. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  54. Ashoor, G.; Syngelaki, A.; Poon, L.C.; Rezende, J.C.; Nicolaides, K.H. Fetal fraction in maternal plasma cell-free DNA at 11–13 weeks’ gestation: Relation to maternal and fetal characteristics. Ultrasound Obstet. Gynecol. 2013, 41, 26–32. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  55. Suzumori, N.; Ebara, T.; Yamada, T.; Samura, O.; Yotsumoto, J.; Nishiyama, M.; Miura, K.; Sawai, H.; Murotsuki, J.; Kitagawa, M.; et al. Japan NIPT Consortium. Fetal cell-free DNA fraction in maternal plasma is affected by fetal trisomy. J. Hum. Genet. 2016, 61, 647–652. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  56. Dobson, L.J.; Reiff, E.S.; Little, S.E.; Wilkins-Haug, L.; Bromley, B. Patient choice and clinical outcomes following positive noninvasive prenatal screening for aneuploidy with cell-free DNA (cfDNA). Prenat. Diagn. 2016, 36, 456–462. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  57. Piechan, J.L.; Hines, K.A.; Koller, D.L.; Stone, K.; Quaid, K.; Torres-Martinez, W.; Wilson Mathews, D.; Foroud, T.; Cook, L. NIPT and Informed Consent: An Assessment of Patient Understanding of a Negative NIPT Result. J. Genet. Couns. 2016, 25, 1127–1137. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  58. American College of Obstetricians and Gynecologists. Committee Opinion No. 640: Cell-Free DNA Screening for Fetal Aneuploidy. Obstet. Gynecol. 2015, 126, e31–e37. [Google Scholar] [CrossRef] [PubMed]
  59. Bianchi, D.W.; Chudova, D.; Sehnert, A.J.; Bhatt, S.; Murray, K.; Prosen, T.L.; Garber, J.E.; Wilkins-Haug, L.; Vora, N.L.; Warsof, S.; et al. Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies. JAMA 2015, 314, 162–169. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  60. Kunpalin, Y.; Richter, J.; Mufti, N.; Bosteels, J.; Ourselin, S.; De Coppi, P.; Thompson, D.; David, A.L.; Deprest, J. Cranial findings detected by second-trimester ultrasound in fetuses with myelomeningocele: A systematic review. BJOG Int. J. Obstet. Gynaecol. 2021, 128, 366–374. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  61. Giorgione, V.; Haratz, K.K.; Constantini, S.; Birnbaum, R.; Malinger, G. Fetal cerebral ventriculomegaly: What do we tell the prospective parents? Prenat. Diagn. 2022, 42, 1674–1681. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  62. Maheut-Lourmière, J.; Paillet, C. Prenatal diagnosis of anomalies of the corpus callosum with ultrasound: The echographist’s point of view. Neurochirurgie 1998, 44, 85–92. (In French) [Google Scholar] [PubMed]
  63. Albu, C.C.; Albu, D.F.; Pătraşcu, A.; Albu, Ş.D.; Efrem, I.C.; Gogănău, A.M. Prenatal diagnosis of syndromic alobar holoprosencephaly associated with digynic triploidy fetus. Rom. J. Morphol. Embryol. 2020, 61, 1309–1316. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  64. Alam, A.; Chander, B.N.; Bhatia, M. Dandy-Walker Variant: Prenatal Diagnosis by Ultrasonography. Med. J. Armed Forces India 2004, 60, 287–289. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  65. Méndez, A.G.; Mena, A.H.; Aguilar, F.A.; Segura, J.A.R.; Guerrero, M.Á.G. Fetal surgery for occipital encephalocele: A case report. Surg. Neurol. Int. 2023, 14, 433. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  66. Sadineni, R.T.; Kumar, B.S.; Chander, N.B.; Boppana, D.M. Prenatal Sonographic Diagnosis of Hypoplastic Left Heart Syndrome. Int. J. Appl. Basic Med. Res. 2017, 7, 213–215. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  67. Deng, D.P.; Qian, T.; Liu, Y.H.; Wu, Z.S.; Lu, T. Prenatal diagnosis, management, and outcomes of fetuses with tetralogy of Fallot in China after prenatal counseling: A prospective cohort study. Front. Pediatr. 2023, 11, 1172282. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  68. Shinebourne, E.A.; Babu-Narayan, S.V.; Carvalho, J.S. Tetralogy of Fallot: From fetus to adult. Heart 2006, 92, 1353–1359. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  69. Clausen, A.B.; Garne, E.; Damkjær, M. Live birth prevalence of atrioventricular septal defect after the implementation of new prenatal screening guidelines. Dan. Med. J. 2022, 69, A09210676. [Google Scholar] [PubMed]
  70. Masoller, N.; Gómez Del Rincón, O.; Herraiz, I.; Gómez-Montes, E.; Soveral, I.; Pérez-Cruz, M.; Martínez-Biosques, C.; Granados, M.A.; Bennasar, M.; Escobar-Diaz, M.C.; et al. Prediction of Perinatal Mortality in Ebstein’s Anomaly Diagnosed in the Second Trimester of Pregnancy. Fetal Diagn. Ther. 2020, 47, 604–614. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  71. Smarius, B.; Loozen, C.; Manten, W.; Bekker, M.; Pistorius, L.; Breugem, C. Accurate diagnosis of prenatal cleft lip/palate by understanding the embryology. World J. Methodol. 2017, 7, 93–100. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  72. Cang, Z.; Cui, J.; Pei, J.; Wang, Z.; Du, Y.; Mu, S.; Dou, W.; Fan, X.; Zhang, X.; Li, Y. Prenatal diagnosis of micrognathia: A systematic review. Front. Pediatr. 2023, 11, 1161421. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  73. Bangma, M.; Lunshof, S.; Opstal, D.V.; Galjaard, R.J.; Papatsonis, D.N. Prenatal diagnosis of alobar holoprosencephaly, cyclopia, proboscis, and isochromosome 18q in the second trimester. Am. J. Perinatol. Rep. 2011, 1, 73–76. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  74. Graham, G.; Devine, P.C. Antenatal diagnosis of congenital diaphragmatic hernia. Semin. Perinatol. 2005, 29, 69–76. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  75. Liang, Y.L.; Kang, L.; Tsai, P.Y.; Cheng, Y.C.; Ko, H.C.; Chang, C.H.; Chang, F.M. Prenatal diagnosis of fetal omphalocele by ultrasound: A comparison of two centuries. Taiwan J. Obstet. Gynecol. 2013, 52, 258–263. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  76. Daskalakis, G.; Pilalis, A.; Papadopoulos, D.; Antsaklis, A. Body stalk anomaly diagnosed in the 2nd trimester. Fetal Diagn Ther. 2003, 18, 342–344. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  77. Huber, C.; Shazly, S.A.; Blumenfeld, Y.J.; Jelin, E.; Ruano, R. Update on the Prenatal Diagnosis and Outcomes of Fetal Bilateral Renal Agenesis. Obstet. Gynecol. Surv. 2019, 74, 298–302. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  78. Simonini, C.; Fröschen, E.M.; Nadal, J.; Strizek, B.; Berg, C.; Geipel, A.; Gembruch, U. Prenatal ultrasound in fetuses with polycystic kidney appearance—Expanding the diagnostic algorithm. Arch. Gynecol. Obstet. 2023, 308, 1287–1300. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  79. Mustafa, H.J.; Khalil, A.; Johnson, S.; Gordijn, S.J.; Ganzevoort, W.; Melling, C.; Koh, C.J.; Mandy, G.T.; Kilby, M.D.; Johnson, A.; et al. Fetal lower urinary tract obstruction: International Delphi consensus on management and core outcome set. Ultrasound Obstet. Gynecol. 2024, 64, 635–650. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  80. Chitty, L.S.; Khalil, A.; Barrett, A.N.; Pajkrt, E.; Griffin, D.R.; Cole, T.J. Safe, accurate, prenatal diagnosis of thanatophoric dysplasia using ultrasound and free fetal DNA. Prenat. Diagn. 2013, 33, 416–423. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  81. Wang, W.; Wu, Q.; Sun, L.; Zhong, X.; Xu, Y.; Xie, X.; Su, Z. Diagnosis of Prenatal-Onset Achondrogenesis Type II by a Multidisciplinary Assessment: A Retrospective Study of 2 Cases. Case Rep. Obstet. Gynecol. 2019, 2019, 7981767. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  82. de Souza Lima, T.; Ferreira, B.G.; Loureiro Souza, C.W.; Batista, I.B.C.; Araujo Júnior, E.; Galvão Petrini, C.; Paschoini, M.C.; Peixoto, A.B. Prenatal diagnosis of diastrophic dysplasia in the second trimester of pregnancy: Two- and three- dimensional ultrasonographic findings. Turk. J. Obstet. Gynecol. 2021, 18, 258–263. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  83. Abdallah, W.; Nassar, M. Outcome of prenatal diagnosis of clubfoot: A single institution experience. Future Sci. OA 2021, 8, FSO773. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  84. Shi, Y.; Zhang, B.; Kong, F.; Li, X. Prenatal limb defects: Epidemiologic characteristics and an epidemiologic analysis of risk factors. Medicine 2018, 97, e11471. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  85. Abiad, M.; Zargarzadeh, N.; Javinani, A.; Krispin, E.; Shamshirsaz, A.A. Fetal Teratomas: Advances in Diagnosis and Management. J. Clin. Med. 2024, 13, 6245. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  86. Abubeker, F.A.; Tufa, T.H.; Shiferaw, M.A.; Feyssa, M.D.; Gudu, W.; Bekele, D.; Prager, S. Successful dilation and evacuation for second trimester conjoined twin: A case report and review of the literature. J. Med. Case Rep. 2021, 15, 298. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  87. Gedikbaşı, A.; Yıldırım, G.; Saygılı, S.; Ismayilzade, R.; Gül, A.; Ceylan, Y. Prenatal diagnosis of conjoined twins: Four cases in a prenatal center. J. Turk. Ger. Gynecol. Assoc. 2010, 11, 174–177. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  88. American College of Obstetricians and Gynecologists. Practice Bulletin No. 162: Prenatal Diagnostic Testing for Genetic Disorders. Obstet. Gynecol. 2016, 127, e108–e122. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  89. Baffero, G.M.; Somigliana, E.; Crovetto, F.; Paffoni, A.; Persico, N.; Guerneri, S.; Lalatta, F.; Fogliani, R.; Fedele, L. Confined placental mosaicism at chorionic villous sampling: Risk factors and pregnancy outcome. Prenat. Diagn. 2012, 32, 1102–1108. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  90. Akolekar, R.; Beta, J.; Picciarelli, G.; Ogilvie, C.; D’Antonio, F. Procedure-related risk of miscarriage following amniocentesis and chorionic villus sampling: A systematic review and meta-analysis. Ultrasound Obstet. Gynecol. 2015, 45, 16–26. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  91. Society for Maternal-Fetal Medicine (SMFM); Dugoff, L.; Norton, M.E.; Kuller, J.A. The use of chromosomal microarray for prenatal diagnosis. Am. J. Obstet. Gynecol. 2016, 215, B2–B9, Erratum in Am. J. Obstet. Gynecol. 2017, 216, 180. https://doi.org/10.1016/j.ajog.2016.11.1031. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  92. Tepperberg, J.; Pettenati, M.J.; Rao, P.N.; Lese, C.M.; Rita, D.; Wyandt, H.; Gersen, S.; White, B.; Schoonmaker, M.M. Prenatal diagnosis using interphase fluorescence in situ hybridization (FISH): 2-year multi-center retrospective study and review of the literature. Prenat. Diagn. 2001, 21, 293–301. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  93. Wapner, R.J.; Martin, C.L.; Levy, B.; Ballif, B.C.; Eng, C.M.; Zachary, J.M.; Savage, M.; Platt, L.D.; Saltzman, D.; Grobman, W.A.; et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. N. Engl. J. Med. 2012, 367, 2175–2184. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  94. Audibert, F.; Wilson, R.D.; Allen, V.; Blight, C.; Brock, J.A.; Désilets, V.A.; Gagnon, A.; Johnson, J.A.; Langlois, S.; Wyatt, P. Genetics Committee. Preimplantation genetic testing. J. Obstet. Gynaecol. Can. 2009, 31, 761–775. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  95. DeUgarte, C.M.; Li, M.; Surrey, M.; Danzer, H.; Hill, D.; DeCherney, A.H. Accuracy of FISH analysis in predicting chromosomal status in patients undergoing preimplantation genetic diagnosis. Fertil. Steril. 2008, 90, 1049–1054. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  96. Ventura, S.J.; Taffel, S.M.; Mosher, W.D. Estimates of pregnancies and pregnancy rates for the United States, 1976–1985. Am. J. Public Health 1988, 78, 506–511. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  97. Bose, S.; Trent, K. Socio-demographic determinants of abortion in India: A north-South comparison. J. Biosoc. Sci. 2006, 38, 261–282, Erratum in J. Biosoc. Sci. 2006, 38, 283. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  98. Söderberg, H.; Andersson, C.; Janzon, L.; Sjöberg, N.O. Socio-demographic characteristics of women requesting induced abortion. A cross-sectional study from the municipality of Malmö, Sweden. Acta Obstet. Gynecol. Scand. 1993, 72, 365–368. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  99. Uria, M.; Mosquera, C. Legal abortion in Asturias (Spain) after the 1985 law: Sociodemographic characteristics of women applying for abortion. Eur. J. Epidemiol. 1999, 15, 59–64. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  100. Mulat, A.; Bayu, H.; Mellie, H.; Alemu, A. Induced second trimester abortion and associated factors in Amhara region referral hospitals. Biomed. Res. Int. 2015, 2015, 256534. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  101. Figà-Talamanca, I.; Grandolfo, M.E.; Spinelli, A. Epidemiology of legal abortion in Italy. Int. J. Epidemiol. 1986, 15, 343–351. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  102. Chibber, K.S.; Biggs, M.A.; Roberts, S.C.; Foster, D.G. The role of intimate partners in women’s reasons for seeking abortion. Women’s Health Issues 2014, 24, e131–e138. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  103. Rasch, V.; Gammeltoft, T.; Knudsen, L.B.; Tobiassen, C.; Ginzel, A.; Kempf, L. Induced abortion in Denmark: Effect of socio-economic situation and country of birth. Eur. J. Public Health 2008, 18, 144–149. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  104. Taft, A.J.; Watson, L.F. Termination of pregnancy: Associations with partner violence and other factors in a national cohort of young Australian women. Aust. N. Zeal. J. Public Health 2007, 31, 135–142. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  105. Cameron, S.T.; Riddell, J.; Brown, A.; Thomson, A.; Melville, C.; Flett, G.; Caird, L.; Laird, G. Characteristics of women who present for abortion towards the end of the mid-trimester in Scotland: National audit 2013–2014. Eur. J. Contracept. Reprod. Health Care 2016, 21, 183–188. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  106. Font-Ribera, L.; Pérez, G.; Salvador, J.; Borrell, C. Socioeconomic inequalities in unintended pregnancy and abortion decision. J. Urban Health 2008, 85, 125–135. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  107. Dehlendorf, C.; Harris, L.H.; Weitz, T.A. Disparities in abortion rates: A public health approach. Am. J. Public Health 2013, 103, 1772–1779. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  108. Pérez, G.; Ruiz-Muñoz, D.; Gotsens, M.; Cases, M.C.; Rodríguez-Sanz, M. Social and economic inequalities in induced abortion in Spain as a function of individual and contextual factors. Eur. J. Public Health 2014, 24, 162–169. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  109. Cheng, D.; Schwarz, E.B.; Douglas, E.; Horon, I. Unintended pregnancy and associated maternal preconception, prenatal and postpartum behaviors. Contraception 2009, 79, 194–198. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  110. Cope, H.; Garrett, M.E.; Gregory, S.; Ashley-Koch, A. Pregnancy continuation and organizational religious activity following prenatal diagnosis of a lethal fetal defect are associated with improved psychological outcome. Prenat. Diagn. 2015, 35, 761–768. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  111. Zaręba, K.; Ciebiera, M.; Bińkowska, M.; Jakiel, G. Moral dilemmas of women undergoing pregnancy termination for medical reasons in Poland. Eur. J. Contracept. Reprod. Health Care 2017, 22, 305–309. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  112. Bacchus, L.; Mezey, G.; Bewley, S. A qualitative exploration of the nature of domestic violence in pregnancy. Violence Against Women 2006, 12, 588–604. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  113. Steinberg, J.R.; Finer, L.B. Examining the association of abortion history and current mental health: A reanalysis of the National Comorbidity Survey using a common-risk-factors model. Soc. Sci. Med. 2011, 72, 72–82. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  114. Munk-Olsen, T.; Laursen, T.M.; Pedersen, C.B.; Lidegaard, Ø.; Mortensen, P.B. Induced first-trimester abortion and risk of mental disorder. N. Engl. J. Med. 2011, 364, 332–339. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  115. Steinberg, J.R.; Russo, N.F. Abortion and anxiety: What’s the relationship? Soc. Sci. Med. 2008, 67, 238–252. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  116. Kooistra, P.A.; Vastbinder, M.B.; Lagro-Janssen, A.L. No increase in medical consumption in general practice after induced abortion. Ned. Tijdschr. Voor Geneeskd. 2007, 151, 409–413. (In Dutch) [Google Scholar] [PubMed]
  117. Mota, N.P.; Burnett, M.; Sareen, J. Associations between abortion, mental disorders, and suicidal behaviour in a nationally representative sample. Can. J. Psychiatry 2010, 55, 239–247. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  118. van Ditzhuijzen, J.; ten Have, M.; de Graaf, R.; van Nijnatten, C.H.; Vollebergh, W.A. Psychiatric history of women who have had an abortion. J. Psychiatr. Res. 2013, 47, 1737–1743. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  119. Hofberg, K.; Ward, M.R. Fear of pregnancy and childbirth. Postgrad. Med. J. 2003, 79, 505–510. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  120. Richards, N.; Reith, D.; Stitely, M.; Smith, A. Antiepileptic drug exposure in pregnancy and pregnancy outcome from national drug usage data. BMC Pregnancy Childbirth 2018, 18, 84. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  121. Marchocki, Z.; Russell, N.E.; Donoghue, K.O. Selective serotonin reuptake inhibitors and pregnancy: A review of maternal, fetal and neonatal risks and benefits. Obstet. Med. 2013, 6, 155–158. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  122. De Genna, N.M.; Feske, U.; Larkby, C.; Angiolieri, T.; Gold, M.A. Pregnancies, abortions, and births among women with and without borderline personality disorder. Women’s Health Issues 2012, 22, e371–e377. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  123. Chen, E.Y.; Brown, M.Z.; Lo, T.T.; Linehan, M.M. Sexually transmitted disease rates and high-risk sexual behaviors in borderline personality disorder versus borderline personality disorder with substance use disorder. J. Nerv. Ment. Dis. 2007, 195, 125–129. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  124. Steinberg, J.R.; Tschann, J.M.; Furgerson, D.; Harper, C.C. Psychosocial factors and pre-abortion psychological health: The significance of stigma. Soc. Sci. Med. 2016, 150, 67–75. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  125. Wallin Lundell, I.; Sundström Poromaa, I.; Frans, O.; Helström, L.; Högberg, U.; Moby, L.; Nyberg, S.; Sydsjö, G.; Georgsson Öhman, S.; Östlund, I.; et al. The prevalence of posttraumatic stress among women requesting induced abortion. Eur. J. Contracept. Reprod. Health Care 2013, 18, 480–488. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  126. Simoila, L.; Isometsä, E.; Gissler, M.; Suvisaari, J.; Sailas, E.; Halmesmäki, E.; Lindberg, N. Schizophrenia and induced abortions: A national register-based follow-up study among Finnish women born between 1965–1980 with schizophrenia or schizoaffective disorder. Schizophr. Res. 2018, 192, 142–147. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  127. Jenkins, A.; Millar, S.; Robins, J. Denial of pregnancy: A literature review and discussion of ethical and legal issues. J. R. Soc. Med. 2011, 104, 286–291. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  128. Jablensky, A.V.; Morgan, V.; Zubrick, S.R.; Bower, C.; Yellachich, L.A. Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am. J. Psychiatry 2005, 162, 79–91. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  129. Babbitt, K.E.; Bailey, K.J.; Coverdale, J.H.; Chervenak, F.A.; McCullough, L.B. Professionally responsible intrapartum management of patients with major mental disorders. Am. J. Obstet. Gynecol. 2014, 210, 27–31. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  130. Roberts, S.C.; Avalos, L.A.; Sinkford, D.; Foster, D.G. Alcohol, tobacco and drug use as reasons for abortion. Alcohol Alcohol. 2012, 47, 640–648. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  131. Diehl, A.; Pillon, S.C.; Santos, M.A.D.; Laranjeira, R. Abortion and sex-related conditions in substance-dependent Brazilian patients. Cad. Saude Publica 2017, 33, e00143416. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  132. Lehti, V.; Sourander, A.; Polo-Kantola, P.; Sillanmäki, L.; Tamminen, T.; Kumpulainen, K. Association between childhood psychosocial factors and induced abortion. Eur. J. Obstet. Gynecol. Reprod. Biol. 2013, 166, 190–195. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  133. O’Brien, K.M.; Whelan, D.R.; Sandler, D.P.; Hall, J.E.; Weinberg, C.R. Predictors and long-term health outcomes of eating disorders. PLoS ONE 2017, 12, e0181104. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  134. Bulik, C.M.; Hoffman, E.R.; Von Holle, A.; Torgersen, L.; Stoltenberg, C.; Reichborn-Kjennerud, T. Unplanned pregnancy in women with anorexia nervosa. Obstet. Gynecol. 2010, 116, 1136–1140. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  135. Roller, C.G. Sexually compulsive/addictive behaviors in women: A women’s healthcare issue. J. Midwifery Women’s Health 2007, 52, 486–491. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  136. Fergusson, D.M.; Horwood, L.J.; Boden, J.M. Abortion and mental health disorders: Evidence from a 30-year longitudinal study. Br. J. Psychiatry 2008, 193, 444–451. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  137. Davies, V.; Gledhill, J.; McFadyen, A.; Whitlow, B.; Economides, D. Psychological outcome in women undergoing termination of pregnancy for ultrasound-detected fetal anomaly in the first and second trimesters: A pilot study. Ultrasound Obstet. Gynecol. 2005, 25, 389–392. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  138. Freeman, E.W.; Rickels, K.; Huggins, G.R.; Garcia, C.R.; Polin, J. Emotional distress patterns among women having first or repeat abortions. Obstet. Gynecol. 1980, 55, 630–636. [Google Scholar] [PubMed]
  139. Di Febo, R.; D’Aloise, A.; Anselmi, N.; Leone, C.; Pezzuti, L. Psychological implications of abortion: A longitudinal study on two cohorts of women who recur to elective and therapeutic abortion. Riv. Psichiatr. 2018, 53, 324–330. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  140. Cohen, L.; Roth, S. Coping with abortion. J. Hum. Stress 1984, 10, 140–145. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  141. Niswander, K.R.; Patterson, R.J. Psychologic reaction to therapeutic abortion. I. Subjective patient response. Obstet. Gynecol. 1967, 29, 702–706. [Google Scholar] [PubMed]
  142. Major, B.; Mueller, P.; Hildebrandt, K. Attributions, expectations, and coping with abortion. J. Pers. Soc. Psychol. 1985, 48, 585–599. [Google Scholar] [CrossRef] [PubMed]
  143. Kersting, A.; Kroker, K.; Steinhard, J.; Hoernig-Franz, I.; Wesselmann, U.; Luedorff, K.; Ohrmann, P.; Arolt, V.; Suslow, T. Psychological impact on women after second and third trimester termination of pregnancy due to fetal anomalies versus women after preterm birth—A 14-month follow up study. Arch. Women’s Ment. Health 2009, 12, 193–201. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  144. Korenromp, M.J.; Christiaens, G.C.; van den Bout, J.; Mulder, E.J.; Hunfeld, J.A.; Bilardo, C.M.; Offermans, J.P.; Visser, G.H. Long-term psychological consequences of pregnancy termination for fetal abnormality: A cross-sectional study. Prenat. Diagn. 2005, 25, 253–260. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  145. Sullins, D.P. Affective and Substance Abuse Disorders Following Abortion by Pregnancy Intention in the United States: A Longitudinal Cohort Study. Medicina 2019, 55, 741. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  146. Mahé, V.; Dumaine, A. Oestrogen withdrawal associated psychoses. Acta Psychiatr. Scand. 2001, 104, 323–331. [Google Scholar] [CrossRef] [PubMed]
  147. Mahe, V.; Montagnon, F.; Nartowski, J.; Dumane, A. Post-abortion mania. Br. J. Psychiatry 1999, 175, 389–390. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  148. Donnai, P.; Charles, N.; Harris, R. Attitudes of patients after “genetic” termination of pregnancy. Br. Med. J. (Clin. Res. Ed.) 1981, 282, 621–622. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  149. Blumberg, B.D.; Golbus, M.S.; Hanson, K.H. The psychological sequelae of abortion performed for a genetic indication. Am. J. Obstet. Gynecol. 1975, 122, 799–808. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  150. Payne, E.C.; Kravitz, A.R.; Notman, M.T.; Anderson, J.V. Outcome following therapeutic abortion. Arch. Gen. Psychiatry 1976, 33, 725–733. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  151. Romans-Clarkson, S.E. Psychological sequelae of induced abortion. Aust. N. Zeal. J. Psychiatry 1989, 23, 555–565. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  152. Dagg, P.K. The psychological sequelae of therapeutic abortion--denied and completed. Am. J. Psychiatry 1991, 148, 578–585. [Google Scholar] [CrossRef] [Scilit]
  153. Bracken, M.B.; Klerman, L.V.; Bracken, M. Coping with pregnancy resolution among never-married women. Am. J. Orthopsychiatry 1978, 48, 320–334. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  154. Athanasiou, R.; Oppel, W.; Michelson, L.; Unger, T.; Yager, M. Psychiatric sequelae to term birth and induced early and late abortion: A longitudinal study. Fam. Plan. Perspect. 1973, 5, 227–231. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  155. Diggory, P.L. Some experiences of therapeutic abortion. Lancet 1969, 1, 873–875. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  156. Kotta, S.; Molangur, U.; Bipeta, R.; Ganesh, R. A Cross-Sectional Study of the Psychosocial Problems Following Abortion. Indian J. Psychiatry 2018, 60, 217–223. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  157. Vayssière, C.; Gaudineau, A.; Attali, L.; Bettahar, K.; Eyraud, S.; Faucher, P.; Fournet, P.; Hassoun, D.; Hatchuel, M.; Jamin, C.; et al. Elective abortion: Clinical practice guidelines from the French College of Gynecologists and Obstetricians (CNGOF). Eur. J. Obstet. Gynecol. Reprod. Biol. 2018, 222, 95–101. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  158. Smith, B.E.Y.; Bartz, D.; Goldberg, A.B.; Janiak, E. “Without any indication”: Stigma and a hidden curriculum within medical students’ discussion of elective abortion. Soc. Sci. Med. 2018, 214, 26–34. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  159. Kulier, R.; Kapp, N.; Gülmezoglu, A.M.; Hofmeyr, G.J.; Cheng, L.; Campana, A. Medical methods for first trimester abortion. Cochrane Database Syst. Rev. 2011, 2011, CD002855, Correction in Cochrane Database Syst. Rev. 2022, 5, CD002855. https://doi.org/10.1002/14651858.CD002855.pub5. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  160. Bracken, H.; Clark, W.; Lichtenberg, E.S.; Schweikert, S.M.; Tanenhaus, J.; Barajas, A.; Alpert, L.; Winikoff, B. Alternatives to routine ultrasound for eligibility assessment prior to early termination of pregnancy with mifepristone-misoprostol. BJOG Int. J. Obstet. Gynaecol. 2011, 118, 17–23. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  161. Costescu, D.; Guilbert, E.; Bernardin, J.; Black, A.; Dunn, S.; Fitzsimmons, B.; Norman, W.V.; Pymar, H.; Soon, J.; Trouton, K.; et al. Society of Obstetricians and Gynecologists of Canada. Medical Abortion. J. Obstet. Gynaecol. Can. 2016, 38, 366–389, Erratum in J. Obstet. Gynaecol. Can. 2017, 39, 67. https://doi.org/10.1016/j.jogc.2016.07.009. (In English, French). [Google Scholar] [CrossRef] [Scilit] [PubMed]
  162. Blum, J.; Raghavan, S.; Dabash, R.; Nga, N.T.B.; Chelli, H.; Hajri, S.; Conkling, K.; Winikoff, B. Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam. Int. J. Gynaecol. Obstet. 2012, 118, 166–171. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  163. Ngoc, N.T.; Blum, J.; Raghavan, S.; Nga, N.T.; Dabash, R.; Diop, A.; Winikoff, B. Comparing two early medical abortion regimens: Mifepristone+misoprostol vs. misoprostol alone. Contraception 2011, 83, 410–417. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  164. Colwill, A.C.; Bayer, L.L.; Bednarek, P.; Garg, B.; Jensen, J.T.; Edelman, A.B. Opioid Analgesia for Medical Abortion: A Randomized Controlled Trial. Obstet. Gynecol. 2019, 134, 1163–1170. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  165. American College of Obstetricians and Gynecologists. Practice bulletin no. 143: Medical management of first-trimester abortion. Obstet. Gynecol. 2014, 123, 676–692. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  166. Schmidt-Hansen, M.; Cameron, S.; Lohr, P.A.; Hasler, E. Follow-up strategies to confirm the success of medical abortion of pregnancies up to 10 weeks’ gestation: A systematic review with meta-analyses. Am. J. Obstet. Gynecol. 2020, 222, 551–563.e13. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  167. Fiala, C.; Safar, P.; Bygdeman, M.; Gemzell-Danielsson, K. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur. J. Obstet. Gynecol. Reprod. Biol. 2003, 109, 190–195. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  168. Pocius, K.D.; Bartz, D.; Maurer, R.; Stenquist, A.; Fortin, J.; Goldberg, A.B. Serum human chorionic gonadotropin (hCG) trend within the first few days after medical abortion: A prospective study. Contraception 2017, 95, 263–268. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  169. Chen, M.J.; Creinin, M.D. Mifepristone with Buccal Misoprostol for Medical Abortion: A Systematic Review. Obstet. Gynecol. 2015, 126, 12–21. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  170. Reeves, M.F.; Kudva, A.; Creinin, M.D. Medical abortion outcomes after a second dose of misoprostol for persistent gestational sac. Contraception 2008, 78, 332–335. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  171. Reeves, M.F.; Monmaney, J.A.; Creinin, M.D. Predictors of uterine evacuation following early medical abortion with mifepristone and misoprostol. Contraception 2016, 93, 119–125. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  172. Darney, P.D.; Atkinson, E.; Hirabayashi, K. Uterine perforation during second-trimester abortion by cervical dilation and instrumental extraction: A review of 15 cases. Obstet Gynecol. 1990, 75, 441–444. [Google Scholar] [PubMed]
  173. Darney, P.D.; Sweet, R.L. Routine intraoperative ultrasonography for second trimester abortion reduces incidence of uterine perforation. J. Ultrasound Med. 1989, 8, 71–75. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  174. Kerns, J.; Steinauer, J. Management of postabortion hemorrhage: Release date November 2012 SFP Guideline #20131. Contraception 2013, 87, 331–342. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  175. Meirik, O.; Huong, M.N.T.; Piaggio, G.; Bergel, E.; von Hertzen, H.; WHO Research Group on Postovulatory Methods of Fertility Regulation. Complications of first-trimester abortion by vacuum aspiration after cervical preparation with and without misoprostol: A multicentre randomised trial. Lancet 2012, 379, 1817–1824, Erratum in Lancet 2012, 379, 2342. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  176. Kinsner-Ovaskainen, A.; Lanzoni, M.; Garne, E.; Loane, M.; Morris, J.; Neville, A.; Nicholl, C.; Rankin, J.; Rissmann, A.; Tucker, D.; et al. A sustainable solution for the activities of the European network for surveillance of congenital anomalies: EUROCAT as part of the EU Platform on Rare Diseases Registration. Eur. J. Med. Genet. 2018, 61, 513–517. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  177. Tucker, F.D.; Morris, J.K.; Neville, A.; Garne, E.; Kinsner-Ovaskainen, A.; Lanzoni, M.; Loane, M.A.; Martin, S.; Nicholl, C.; Rankin, J.; et al. EUROCAT: An update on its functions and activities. J. Community Genet. 2018, 9, 407–410. [Google Scholar] [CrossRef] [Scilit]
  178. Martin, S.; de la Cruz, J.; Lanzoni, M.; Nicholl, C. Transfer of the Central Database and Coordinating Activities of EUROCAT to the JRC; Publications Office of the European Union: Luxembourg, 2016. [Google Scholar] [CrossRef]
  179. Bergman, J.E.H.; Perraud, A.; Barišić, I.; Kinsner-Ovaskainen, A.; Morris, J.K.; Tucker, D.; Wellesley, D.; Garne, E. Updated EUROCAT guidelines for classification of cases with congenital anomalies. Birth Defects Res. 2024, 116, e2314. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  180. Loane, M.; Dolk, H.; Kelly, A.; Teljeur, C.; Greenlees, R.; Densem, J.; EUROCAT Working Group. Paper 4: EUROCAT statistical monitoring: Identification and investigation of ten year trends of congenital anomalies in Europe. Birth Defects Res. A Clin. Mol. Teratol. 2011, 91, S31–S43. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  181. Kinsner-Ovaskainen, A.; Perraud, A.; Lanzoni, M.; Morris, J.; Garne, E. European Monitoring of Congenital Anomalies: JRC-EUROCAT Report on Statistical Monitoring of Congenital Anomalies (2009–2018); European Commission: Ispra, Italy, 2021; JRC127007; Available online: https://eu-rd-platform.jrc.ec.europa.eu/system/files/public/EUROCAT-Statistical-Monitoring-Report-2021.pdf (accessed on 2 March 2026).
  182. Lanzoni, M.; Morris, J.; Garne, E.; Loane, M.; Kinsner-Ovaskainen, A. European Monitoring of Congenital Anomalies: JRC-EUROCAT Report on Statistical Monitoring of Congenital Anomalies (2007–2016); European Commission: Ispra, Italy, 2019; JRC116876; Available online: https://eu-rd-platform.jrc.ec.europa.eu/sites/default/files/EUROCAT-Stat-Mon-Report-2018.pdf (accessed on 2 March 2026).
  183. Kinsner-Ovaskainen, A.; Perraud, A.; Morris, J.; Garne, E. European Monitoring of Congenital Anomalies: JRC-EUROCAT Report on Statistical Monitoring of Congenital Anomalies (2012–2021); European Commission: Ispra, Italy, 2024; JRC136083; Available online: https://eu-rd-platform.jrc.ec.europa.eu/system/files/public/eurocat/2024_EUROCAT_Statistical_Monitoring_Report.pdf (accessed on 2 March 2026).
  184. Kinsner-Ovaskainen, A.; Perraud, A.; Morris, J.; Garne, E. European Monitoring of Congenital Anomalies: JRC-EUROCAT Report on Statistical Monitoring of Congenital Anomalies (2010–2019); European Commission: Ispra, Italy, 2023; JRC132424; Available online: https://eu-rd-platform.jrc.ec.europa.eu/system/files/public/eurocat/2023_EUROCAT_Statistical_Monitoring_Report.pdf (accessed on 2 March 2026).
  185. Jacobs, J.P.; Franklin, R.C.G.; Béland, M.J.; Spicer, D.E.; Colan, S.D.; Walters, H.L., 3rd; Bailliard, F.; Houyel, L.; St Louis, J.D.; Lopez, L.; et al. Nomenclature for Pediatric and Congenital Cardiac Care: Unification of Clinical and Administrative Nomenclature—The 2021 International Paediatric and Congenital Cardiac Code (IPCCC) and the Eleventh Revision of the International Classification of Diseases (ICD-11). World J. Pediatr. Congenit. Heart Surg. 2021, 12, E1–E18. [Google Scholar] [CrossRef] [Scilit]
  186. Bouchahda, H.; El Mhabrech, H.; Hamouda, H.B.; Ghanmi, S.; Bouchahda, R.; Soua, H. Prenatal diagnosis of caudal regression syndrome and omphalocele in a fetus of a diabetic mother. Pan. Afr. Med. J. 2017, 27, 128. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  187. Akhaddar, A. Caudal Regression Syndrome (Spinal Thoraco-lumbo-sacro-coccygeal Agenesis). World Neurosurg. 2020, 142, 301–302. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  188. Rasmussen, S.A.; Wong, L.Y.; Yang, Q.; May, K.M.; Friedman, J.M. Population-based analyses of mortality in trisomy 13 and trisomy 18. Pediatrics 2003, 111, 777–784. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  189. Morris, J.K.; Savva, G.M. The risk of fetal loss following a prenatal diagnosis of trisomy 13 or trisomy 18. Am. J. Med. Genet. A 2008, 146A, 827–832. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  190. Won, R.H.; Currier, R.J.; Lorey, F.; Towner, D.R. The timing of demise in fetuses with trisomy 21 and trisomy 18. Prenat. Diagn. 2005, 25, 608–611. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  191. Kinsner-Ovaskainen, A.; Morris, J.; Garne, E.; Loane, M.; Lanzoni, M. European Monitoring of Congenital Anomalies: JRC-EUROCAT Report on Statistical Monitoring of Congenital Anomalies (2008–2017); EUR 30158 EN.; Publications Office of the European Union: Luxembourg, 2020; ISBN 978-92-76-17771-5. JRC120236; Available online: https://publications.jrc.ec.europa.eu/repository/bitstream/JRC120236/eurocat_statmon_report_2020_final_online.pdf (accessed on 2 March 2026).
  192. Garne, E.; Olsen, M.S.; Johnsen, S.P.; Hjortdal, V.E.; Andersen, H.Ø.; Nissen, H.; Søndergaard, L.; Videbaek, J.; Danish Register of Congenital Heart Disease. How do we define congenital heart defects for scientific studies? Congenit. Heart Dis. 2012, 7, 46–49. [Google Scholar] [CrossRef] [Scilit]
  193. Santoro, M.; Coi, A.; Barišić, I.; Pierini, A.; Addor, M.C.; Baldacci, S.; Ballardini, E.; Boban, L.; Braz, P.; Cavero-Carbonell, C.; et al. Epidemiology of Pierre-Robin sequence in Europe: A population-based EUROCAT study. Paediatr. Perinat. Epidemiol. 2021, 35, 530–539. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  194. Kahle, K.T.; Kulkarni, A.V.; Limbrick, D.D., Jr.; Warf, B.C. Hydrocephalus in children. Lancet 2016, 387, 788–799. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  195. Karimy, J.K.; Reeves, B.C.; Damisah, E.; Duy, P.Q.; Antwi, P.; David, W.; Wang, K.; Schiff, S.J.; Limbrick, D.D., Jr.; Alper, S.L.; et al. Inflammation in acquired hydrocephalus: Pathogenic mechanisms and therapeutic targets. Nat. Rev. Neurol. 2020, 16, 285–296. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  196. Knowles, R.L.; Solebo, A.L.; Sampaio, M.A.; Brown, C.R.; Sargent, J.; Oluonye, N.; Rahi, J. Incidence, aetiology and neurodisability associated with severe microcephaly: A national surveillance study. Arch. Dis. Child. 2023, 108, 211–217. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  197. Ragge, N.K.; Subak-Sharpe, I.D.; Collin, J.R. A practical guide to the management of anophthalmia and microphthalmia. Eye 2007, 21, 1290–1300. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  198. Ko, F.; Papadopoulos, M.; Khaw, P.T. Primary congenital glaucoma. Prog. Brain Res. 2015, 221, 177–189. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  199. Bradley, E.A.; Zaidi, A.N. Atrial Septal Defect. Cardiol. Clin. 2020, 38, 317–324. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  200. Rao, P.S. A unified classification for tricuspid atresia. Am. Heart J. 1980, 99, 799–804. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  201. Dick, M.; Fyler, D.C.; Nadas, A.S. Tricuspid atresia: Clinical course in 101 patients. Am. J. Cardiol. 1975, 36, 327–337. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  202. Martín-Del-Campo, M.; Rosales-Ibañez, R.; Rojo, L. Biomaterials for Cleft Lip and Palate Regeneration. Int. J. Mol. Sci. 2019, 20, 2176. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  203. Al Maawali, A.; Skarsgard, E.D. The medical and surgical management of gastroschisis. Early Hum. Dev. 2021, 162, 105459. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  204. Keays, M.A.; Dave, S. Current hypospadias management: Diagnosis, surgical management, and long-term patient-centred outcomes. Can. Urol. Assoc. J. 2017, 11, S48–S53. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  205. Stoll, C.; Alembick, Y.; Roth, M.P. Associated anomalies in Pierre Robin sequence. Am. J. Med. Genet. A. 2023, 191, 2312–2323. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  206. Offiah, A.C. Skeletal Dysplasias: An Overview. Endocr. Dev. 2015, 28, 259–276. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  207. Kumar, A.; Hessini, L.; Mitchell, E.M. Conceptualising abortion stigma. Cult. Health Sex. 2009, 11, 625–639. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  208. Ganatra, B.; Gerdts, C.; Rossier, C.; Johnson, B.R., Jr.; Tunçalp, Ö.; Assifi, A.; Sedgh, G.; Singh, S.; Bankole, A.; Popinchalk, A.; et al. Global, regional, and subregional classification of abortions by safety, 2010–2014: Estimates from a Bayesian hierarchical model. Lancet 2017, 390, 2372–2381, Erratum in Lancet 2017, 390, 2346. https://doi.org/10.1016/S0140-6736(17)32608-9. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  209. Thomson, J.J. A Defense of Abortion. Philos. Public Aff. 1971, 1, 47–66. Available online: https://users.manchester.edu/Facstaff/SSNaragon/Online/texts/235/Thomson,%20Defense%20of%20Abortion.pdf (accessed on 2 March 2026).
  210. Gilligan, C. In a Different Voice: Psychological Theory and Women’s Development; Harvard University Press: Cambridge, MA, USA, 1982; Available online: https://books.google.ro/books?hl=ro&lr=&id=XItMnL7ho2gC&oi=fnd&pg=PR9&ots=6XhENQOgX_&sig=KowQSSzkNlTctgu9AyJXQ29Mq4U&redir_esc=y#v=onepage&q&f=false (accessed on 2 March 2026).
  211. Brabeck, M. Moral Judgment: Theory and Research on Differences between Males and Females. In An Ethic of Care: Feminist and Interdisciplinary Perspectives; Larrabee, M.J., Ed.; Routledge: New York, NY, USA, 1993; pp. 33–48. Available online: https://api.taylorfrancis.com/content/books/mono/download?identifierName=doi&identifierValue=10.4324/9780203760192&type=googlepdf (accessed on 2 March 2026).
  212. Frohwirth, L.; Coleman, M.; Moore, A.M. Managing Religion and Morality Within the Abortion Experience: Qualitative Interviews with Women Obtaining Abortions in the U.S. World Med. Health Policy 2018, 10, 381–400. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  213. Romanian Parliament. Criminal Code of Romania—Law No. 286/2009, Art. 201. Published in the Official Gazette No. 510 of 24 July 2009. Available online: https://legislatie.just.ro/public/detaliidocument/109855 (accessed on 2 March 2026).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.